TWI238161B - HIV replication inhibiting pyrimidines - Google Patents
HIV replication inhibiting pyrimidines Download PDFInfo
- Publication number
- TWI238161B TWI238161B TW088119614A TW88119614A TWI238161B TW I238161 B TWI238161 B TW I238161B TW 088119614 A TW088119614 A TW 088119614A TW 88119614 A TW88119614 A TW 88119614A TW I238161 B TWI238161 B TW I238161B
- Authority
- TW
- Taiwan
- Prior art keywords
- amino
- compound
- scope
- formula
- cyano
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 230000010076 replication Effects 0.000 title description 3
- 150000003230 pyrimidines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- -1 cyano, nitro, amino Chemical group 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 239000001257 hydrogen Substances 0.000 claims abstract description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 29
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 14
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000000543 intermediate Substances 0.000 claims description 58
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 56
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 239000002904 solvent Substances 0.000 claims description 47
- 238000006243 chemical reaction Methods 0.000 claims description 34
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 230000002079 cooperative effect Effects 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 150000001412 amines Chemical class 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 16
- 229910052786 argon Inorganic materials 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 208000031886 HIV Infections Diseases 0.000 claims description 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 9
- 239000012298 atmosphere Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- KXCVRJMSLWDHNJ-UHFFFAOYSA-N 1-(9H-fluoren-1-yl)pyrrolidin-2-one Chemical compound C1(=CC=CC=2C3=CC=CC=C3CC12)N1C(CCC1)=O KXCVRJMSLWDHNJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
- 239000012442 inert solvent Substances 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 4
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 3
- YOTZYFSGUCFUKA-UHFFFAOYSA-N dimethylphosphine Chemical compound CPC YOTZYFSGUCFUKA-UHFFFAOYSA-N 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-NJFSPNSNSA-N ((18)O)water Chemical compound [18OH2] XLYOFNOQVPJJNP-NJFSPNSNSA-N 0.000 claims 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical group NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 claims 1
- 229910000487 osmium oxide Inorganic materials 0.000 claims 1
- JIWAALDUIFCBLV-UHFFFAOYSA-N oxoosmium Chemical compound [Os]=O JIWAALDUIFCBLV-UHFFFAOYSA-N 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000005245 sintering Methods 0.000 claims 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 19
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract description 15
- 125000003277 amino group Chemical group 0.000 abstract description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 8
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 abstract description 8
- 125000004076 pyridyl group Chemical group 0.000 abstract description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract description 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract description 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 238000011049 filling Methods 0.000 description 40
- 239000000460 chlorine Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 22
- 239000002585 base Substances 0.000 description 21
- 239000007787 solid Substances 0.000 description 20
- 229920000858 Cyclodextrin Polymers 0.000 description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 17
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- 239000003480 eluent Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 12
- 238000002390 rotary evaporation Methods 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 230000000798 anti-retroviral effect Effects 0.000 description 6
- 238000013375 chromatographic separation Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 229940097362 cyclodextrins Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000007937 lozenge Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229920003169 water-soluble polymer Polymers 0.000 description 5
- KWVPRPSXBZNOHS-UHFFFAOYSA-N 2,4,6-Trimethylaniline Chemical compound CC1=CC(C)=C(N)C(C)=C1 KWVPRPSXBZNOHS-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 238000010956 selective crystallization Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229960000523 zalcitabine Drugs 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-trimethylbenzene Chemical compound CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 2
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001062472 Stokellia anisodon Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- ZNPKAOCQMDJBIK-UHFFFAOYSA-N nitrocyanamide Chemical compound [O-][N+](=O)NC#N ZNPKAOCQMDJBIK-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052762 osmium Inorganic materials 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000001725 pyrenyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
- UDLAUVFRZXIQJS-UHFFFAOYSA-N 1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1C(=O)CN=CC2=CC=CC=C21 UDLAUVFRZXIQJS-UHFFFAOYSA-N 0.000 description 1
- JXYPNRIYAMXJSE-UHFFFAOYSA-N 1,4-diazepin-6-one Chemical compound O=C1C=NC=CN=C1 JXYPNRIYAMXJSE-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- GLDNZPLPEYLLNS-UHFFFAOYSA-N 2,5,6-trichloropyrimidin-4-amine Chemical compound NC1=NC(Cl)=NC(Cl)=C1Cl GLDNZPLPEYLLNS-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- PBIUDEUWYGBHDW-UHFFFAOYSA-N 2-chloro-1-pyridin-3-ylethanone;hydrochloride Chemical compound Cl.ClCC(=O)C1=CC=CN=C1 PBIUDEUWYGBHDW-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- JYNQKCFJPQEXSL-UHFFFAOYSA-N 2-methylpentan-3-amine Chemical compound CCC(N)C(C)C JYNQKCFJPQEXSL-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MIRQXSRDYNOFBB-UHFFFAOYSA-N 4-[(5-bromo-4-chloropyrimidin-2-yl)amino]benzonitrile Chemical compound C1=C(Br)C(Cl)=NC(NC=2C=CC(=CC=2)C#N)=N1 MIRQXSRDYNOFBB-UHFFFAOYSA-N 0.000 description 1
- KTXLAHKXAQGXAY-UHFFFAOYSA-N 4-[2-(4-cyanoanilino)-5-nitropyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC=C1[N+]([O-])=O KTXLAHKXAQGXAY-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- SWJAAIMAEBSKQZ-UHFFFAOYSA-N 4-[[4-amino-5-chloro-6-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Cl SWJAAIMAEBSKQZ-UHFFFAOYSA-N 0.000 description 1
- SOJXDRPTMGPTRD-UHFFFAOYSA-N 4-[[5-chloro-4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC(NC=2C=CC(=CC=2)C#N)=NC=C1Cl SOJXDRPTMGPTRD-UHFFFAOYSA-N 0.000 description 1
- VUZFTIPOMQDWCC-UHFFFAOYSA-N 4-[[5-nitro-4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC(NC=2C=CC(=CC=2)C#N)=NC=C1[N+]([O-])=O VUZFTIPOMQDWCC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000725476 Geranium sibiricum Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101000913968 Ipomoea purpurea Chalcone synthase C Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 101000907988 Petunia hybrida Chalcone-flavanone isomerase C Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical class CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000747 amidyl group Chemical group [H][N-]* 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- UQHIJFYTOORACA-UHFFFAOYSA-N argon 1H-pyridin-2-one Chemical compound [Ar].N1C(C=CC=C1)=O UQHIJFYTOORACA-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- YECDGJDAVOYGPJ-UHFFFAOYSA-N argon;phenol Chemical compound [Ar].OC1=CC=CC=C1 YECDGJDAVOYGPJ-UHFFFAOYSA-N 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- QBBJFYQPYXKIEB-UHFFFAOYSA-N benzonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N#CC1=CC=CC=C1 QBBJFYQPYXKIEB-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NQUWWUVODYFMSD-UHFFFAOYSA-N cyanosulfamic acid Chemical compound OS(=O)(=O)NC#N NQUWWUVODYFMSD-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZHGASCUQXLPSDT-UHFFFAOYSA-N cyclohexanesulfonic acid Chemical compound OS(=O)(=O)C1CCCCC1 ZHGASCUQXLPSDT-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- LRTFPLFDLJYEKT-UHFFFAOYSA-N para-isopropylaniline Chemical compound CC(C)C1=CC=C(N)C=C1 LRTFPLFDLJYEKT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 229940071182 stannate Drugs 0.000 description 1
- 125000005402 stannate group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005323 thioketone group Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N trifluoromethane acid Natural products FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
Description
1238161 A7 -- _ —— B7 五、發明説明() —----- 本發明係關於具有抑制人類免疫缺乏病毒(hiv)複製 特徵之做衍生物的用途。其亦關於♦定衍生物之新顆種 類,其作為醫藥品之用途,其製備方法及含其之製藥組成 物。 EP-0,834,507中揭示具有抑制勝複製特徵之經取代 的二胺基1,3,5-三畊衍生物。本發明化合物與已知之丨,3,5_ 一σ井類不同處在於結構及在於其改良之抑制hi V複製特 本發明係關於下式(I)化合物,其N-氧化物,製藥上 可接受的加成鹽類,季胺類及立體化學異構型式於製備用 來治療惟患HIV (人類免疫缺乏病毒)感染之病患之醫藥 品的用途, 其中 -ai=a2-a3=a4-代表下式之二價基 鬌 請先閱讀背面之注意事項再填寫本頁 、可 經濟部智慧財產局員工消費合作社印製 _CH=CH-CH=CH_ 养 CH-CH=CH--N=CH-N=CH--N=CH-CH=N--N=N-CH=CH-n 為 0, 1,2, 3 或 4 ;且當-a1 (a-1); (a-2); (a-3); (a-4); (a-5); a2-a3=a4-為(a-1)時,貝ij n 亦可 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 88404a(9JANUSA) 1238161 A7 B7 五、發明説明(2 ) 為5 ; (請先閱讀背面之注意事項再填寫本頁) R1為氫;芳基;曱醯基;CV6烷基羰基;Cw烷基;Cm烷 氧基羰基;被曱醯基,CV6烷基羰基,CV6烷氧基羰 基,Cw烷基羰基氧基取代之CV6烷基;被CV6烷氧基 羰基取代之CV6烷氧基Cw烷基羰基; 每一個R2獨立地為羥基,鹵素,選擇地被氰基或-C(=0)R6 取代之cv6烷基,c3.7環烷基,選擇地被一或多個鹵素 原子或氰基取代之c2.6烯基,選擇地被一或多個鹵素原 子或氰基取代之c2.6炔基,Cw烷氧基,CV6烷氧基羰 基,羧基,氰基,硝基,胺基,單-或二(CV6烷基)胺基, 多鹵素甲基,多鹵素甲氧基,多鹵素甲硫基,-S(=0)pR6, -NH-S(=0)pR6,-C(=0)R6,-NHC(=0)H,-C(=0)NHNH2, -NHC(=0)R6,-C(=NH) R6 或下式之基 其中每一個A獨立地為N,CH或CR6 ; B 為 NH,Ο,S 或 NR6 ; 經濟部智慧財產局員工消費合作社印製 •p為1或2 ;且 R6為曱基,胺基,單-或二曱基胺基或多鹵素曱基; L為Cm烷基,C2_6烯基,C2.1()炔基,C3.7環烷基,其中每 一個該脂族基可被一或二個獨立選自下列之取代基所取 代: * C3.7環烷基, -4- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) l238l6l 五、發明説明(3') "" ~〜~----------------- *吲呼、基或異+朵基,每一個可選擇地被一、二、三 f四個各自獨立選自齒素,k烧基,絲,Clj 氧基,氰基,胺基幾基,確基,胺基,多鹵素甲 基,夕_素曱氧基及cK0烷基羰基之取代基所取 代, *苯基,吡啶基,嘧啶基,吡畊基或嗒畊基,其中每 一個該芳族環可選擇地被一、二、三、四或五個各 自獨立選自定義於R2中之取代基所取代;或 L為-X_R3,其中 R3為苯基,吡啶基,嘧啶基,吡啡基或嗒畊基,其中每 一個該芳族環可選擇地被一、二、三、四或五個各自 獨立選自定義於R2中之取代基所取代;且 X 為-NR1·,.NH-NH·,-N=N-,-〇、_c(=〇)-,-CHOH-,-S-, -S(=0)_*_S(=0)2-; Q代表氫,Cw烷基,鹵素,多鹵素Ci6烷基或-NR4r5 ; 且 經濟部智慧財產局員工消費合作社印製 R及R為各自獨立地選自氫,經基,Ci丨2烧基,cM2烧 氧基’ C^2烷基羰基,cM2烷氧基羰基,芳基,胺基, 單-或二(cv!2烷基)胺基,單-或二(Ci i2烷基)胺基 羰基,其中每一個前述ci i2烷基可選擇地且各獨立地 被一或二各自獨立選自羥基,Ci 6烷氧基,羥基Cl_6烷 氧基’羧基,CV6烧氧基羰基,氰基,胺基,亞胺基, 單·•或二(c1-6烷基)胺基,多鹵素甲基,多鹵素甲氧基, 多鹵素曱硫基,-S(=0)PR6,-NH-S(=0)pR6,-C(=〇)R6, 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X297公釐) 1238161 Α7 Β7 五、發明説明(4 ) •NHC(=0)H,-C(=0)NHNH2,-NHC(=0)R6,-C(=NH)R6 芳 基及Het之取代基所取代;或 R4及R5可一起形成咐σ各ϋ定基,六氫吼唆基,嗎福咐基, 疊氮基或單-或二(C卜丨2烧基)胺基Ci.4亞烧基; Y代表羥基,鹵素,CM環烧基,選擇地被一或多個函素 原子取代之Cw烯基,選擇地被一或多個函素原子取代 之C2_6炔基,被氰基或-C(=0)R6取代之C1-6垸基,cl>>6 烷氧基,Cm烷氧基羰基,羧基,氰基,硝基,胺基, 單-或二(Ck烧基)胺基,多鹵素甲基,多鹵素甲氧基, 多鹵素甲硫基,-S(=0)PR6,-NH-S(=0)PR6,<(==C))r6,_ NHC(=0)H,-C(=0)NHNH2 ’ -NHC(=0)R6,_c(=]SiH)R6 或芳基; 芳基為笨基或被一、二、三、四或五個各自獨立選自齒 素,c!.6烷基,CD環烷基,cv6烷氧基,氰基,硝基, 多鹵素C!_6烷基及多iS素Ck烷氧基之取代基所取代的 苯基; 一
Het為脂族或芳族雜環基;該脂族雜環基係選自吼洛咬 基’六氫σ比咬基’高六氫吼σ定基,六氫咐(U井基,嗎福咐 基,四氫呋喃基及四氫噻吩基,其中每一個該等脂族雜 環基可選擇地被一個酮基所取代;且該芳族雜環基係選 自吼略基,吱喃基’ σ塞吩基,吼σ定基,。密α定基,咐σ井基 及嗒啡基,其中每一個該等芳族雜環基可選擇地被經基 所取代。 本發明亦有關於治療罹患HIV (人類免疫缺乏病毒) -6- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) VI s_al n,^n imMmams a E 0—H Ι··ίρ»» nn I, 請先閱讀背面之注意事項再填寫本頁) 訂 - 經濟部智慧財產局員工消費合作社印製 1238161 A7 B7 五、發明説明(5 感染之溫血動物的方法。該方法包括將治療有效劑量之式 (I)化合物或其N-氧化物型式,製藥上可接受的加成鹽或 立體化學異構型式與製藥載體摻和而給藥。 本發明亦有關於具下式之新穎化合物,其N-氧化 物,加成鹽類,季胺及立體化學異構型式,
(R^q R2a
(I-a) (請先閲讀背面之注意事項再填寫本頁) %衣. 經濟部智慧財產局員工消費合作社印製 其中 代表下式之二價基: -CH=CH-C(R2a)=CH-CH= (b-1); -N=CH-C(R2a)=CH-CH= (b-2); -CH=N-C(R2a)=CH-CH= (b-3); -N=CH-C(R2a)=N-CH= (b-4); -N=CH-C(R2a)=CH-N= (b-5); -CH=N-C(R2a)=N-CH= (b-6); -N=N-C(R2a)=CH-CH= (b-7); a為0, 1,2 ;或a可能為3或4 ; R1為氫;芳基;甲醯基;CV6烷基羰基;Ci.6烷基;心^烷 氧基羰基;被曱醯基,CV6烷基羰基;CV6烷氧基羰 基;CV6烷基羰基氧基取代之CV6烷基;被CV6烷氧基 羰基取代之CN6烷氧基Cw烷基羰基; R2a為氰基,胺基羰基,單-或二(曱基)胺基羰基,被氰 訂 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1238161 A7 B7 五、發明説明(6 ) 基,胺基羰基或單-或二(甲基)胺基羰基取代之cN6 烷基;被氰基取代之c2_6烯基,或被氰基取代之c2_6 炔基; 每一個R2獨立地為羥基,鹵素,選擇地被氰基或-C(=0)R6 取代之C1-6烷基,C3-7環烷基,選擇地被一或多個鹵素 原子或氰基取代之C2_6烯基,選擇地被一或多個鹵素原 子或氰基取代之C2.6炔基;q.6烷氧基;Cle6烷氧基羰 基’魏基’氰基,硕基,胺基,單-或二(C!.6炼基)胺 基,多鹵素曱基,多鹵素甲氧基,多鹵素甲硫基,-S(=0)PR6, -NH-S(=0)pR6,-C(=0)R6,-NHC(=0)H,-C(=0)NHNH2,_ NHC(=0)R6,-C(=NH)R6 或下式之基 ^ (c) 其中每一個A獨立地為N,CH或CR6 ; B 為 NH#,S 或 NR6 ; p為1或2 ;且 R6為甲基,胺基,單•或二曱基胺基或多鹵素甲基; L為* CM0烷基,C2_10烯基,C2_10炔基,C3.7環烷基,其中 每一個該脂族基可被一或二個獨立選自下列之取代基所 取代: * C3.7環烷基, *吲哚基或異吲哚基,每一個可選擇地被一、二、三或 四個各自獨立選自_素,Cw烷基,羥基,CN6烷氧 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐) (請先閲讀背面之注意事項再填寫本頁) ,ιτ 經濟部智慧財產局員工消費合作社印製 1238161 A7 ~ _ B7 五、發明説明(7 ) ---- 基氰基,胺基羰基,硝基,胺基,多_素曱基,多 鹵素甲氧基及CM烷基羰基之取代基所取代, *笨基,吡啶基,嘧啶基,吡畊基或嗒畊基,其中每一 個忒芳族環可選擇地被一、二、三、四或五個各自獨 立選自定義於R2中之取代基所取代;或 L為,其中 R3為苯基,吡啶基,嘧啶基,吼啡基或嗒畊基,其中每一 個該芳族環可選擇地被一,二,三,四或五個各自獨立 選自定義於R2中之取代基所取代;且 X 為-NR1、-NH-NH、-N=N、-〇-,-C(=0)·,-CHOH,-S-,- Q代表氫,Cm烷基,鹵素,多鹵素c16烷基或_NR4r5 ; 且 R4及R5為各自獨立地選自氫,羥基,Ci-12烷基,Ci_i2烷 氧基’ CM2烧基羰基,Ci i2烷氧基羰基,芳基,胺基, 單-或一(C〗]2烧基)胺基,單-或二(Ci_i2烷基)胺基 m基’其中每一個前述C112烷基可選擇地且各自獨立 地被一或二個各自獨立選自羥基,c16烷氧基,羥基 C!_6烷氧基,羧基,.Cw烷氧基羰基,氰基,胺基,亞 fee基’早-或一(C1-6烧基)胺基,多鹵素曱基,多鹵素甲 氧基,多 i 素甲硫基,-S(=0)PR6,-NH-S(=0)PR6,-C(二0)R6,-NHC(=〇)H,-C(=0)NHNH2,-NHC(=0)R6, -C(=NH)R6 ’芳基及Het之取代基所取代;或 R4及R5可一起形成吼略咬基,六氫σ比ti定基,嗎福咐基, 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) i i ---- -------- ^--裝-^ 丨 請先閱讀背面之注意事項再填寫本頁) 訂一* i —Λ, 經濟部智慧財產局員工消費合作社印製 1238161 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(8 ) 疊氮基或單-或二(CM2烷基)胺基c!_4亞烷基; Y代表羥基,i素,c3_7環烷基,選擇地被一或多個鹵素 原子取代之C2·6烯基,選擇地被一或多個_素原子取代 之C2_6炔基,被氰基或-C(=0)R6取代之CK6烷基,Cw 烧氧基’Ck烧氧基幾基,敌基,氰基’硝基,胺基, 單或二(C!_6烧基)胺基,多鹵素甲基,多鹵素甲氧基, 多鹵素甲硫基,-S(=0)PR6,-NH-S.(=0)PR6,-c(=〇)R6, -NHC(=0)H,-C(=0)NHNH2,-NHC(=0)R6,-q=NH)R6 或芳基; 芳基為苯基或被一、二、三、四或五個各自獨立選自齒 素’ Cu烧基’ Cpi哀烧基’ Ck烧氧基’氰基,石肖基, 多鹵素Cw烷基及多i素CV6烷氧基之取代基所取代的 苯基;
Het為脂族或芳族雜環基;該脂族雜環基係選自吼略咬 基,六氫吡啶基,高六氫吡啶基,六氫吡畊基,嗎福唯 基,四氫4喃基及四氫噻吩基,其中每一個該等脂族雜 環基可選擇地一個酮基所取代·’且該芳族雜環基係選自 吡咯基,呋喃基,噻吩基,吡啶基,嘧啶基,吡畊基及 嗒畊基,其中每一個該等芳族雜環基可選擇地被羥基所 取代。 本文中,作為一基或一基之部份的Cw烷基係定義為 直鏈或分支具有由1至6個碳原子之飽和烴基,例如,甲 基,乙基,丙基,1-甲基乙基,丁基,戊基,己基,2•甲 基丙基,2-甲基丁基專,作為一基或一基之部份的Cl 燒 -10- 本紙張尺度適用中國國家標準(CNS ) Α4規格(21 Ox 297公釐) ^ 丨 * · I I. ----- if HI €—1 n ϋ— ϋ ·"""I 85.35?. 請先閱讀背面之注意事項再填寫本頁) 訂 1238161 A7 _____B7 五、發明説明(9 ) 一 基係定義為直鏈或分支具有由1至1〇個碳原子之飽和烴 基,例如定義於c1-6烷基中之基及庚基,辛基,壬基,癸 基等;作為一基或一基之部份的C112烷基係定義為直鏈或 分支具有由1至12個碳原子之飽和烴基,例如定義於cM〇 烷基中之基及十一烷基,十二烷基等;Ci4亞烷基係定義 為直鏈或分支具有由丨至4個碳原子之飽和二價烴基,例 如,亞甲基,1,2-乙二基或ι,2-亞乙基,丨,3_丙二基或 亞丙基,1,4-丁二基或14—亞丁基等;Cp環烷基通常係指 %丙基,裱丁基,環戊基,環己基及環庚基;Gw烯基係 才曰直鏈或分支具有由2至6個碳原子並含有丨個雙鍵之烴 基,例如,乙烯基,丙烯基,丁烯基,戊烯基,己烯基 等;Α·1()烯基定義為直鏈或分支具有由2至1〇個碳原子 並含有1個雙鍵之烴基,例如定義於烯基中之基及庚 烯基,辛烯基,壬烯基,癸稀基等;k絲係定義為直 鏈或刀支具有由2至6個碳原子並含有丨個參鍵之烴基, 例如4絲,丙絲,丁絲,戊絲,己絲等;C2_10 快基係定義為直鏈或分支具有由2至1〇個碳原子並含有i 個茶鍵之烴基,例如定義於c26块基中之基及庚块基,辛 炔基,壬炔基,癸炔基等; 、,山如同前文中者,㈣-詞當連接至一碳原子時形成一 減,當連接-次至-硫原子時形成一亞礙基,且當連接 二次至一硫原子時形成一磺醯基。 函素Θ通系疋才曰氟,氯,溴及峨。如前文及後文中 者,作為一基或一基之部份的多齒素甲基係定義為單-或 -11- t CNS ) A4im ( —------ rl· Li n LI I si ! I! i ii , 請先閱讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 1238161 A7 B7 五、發明説明(10 夕鹵素取代之甲基,特別是具有―或多個氟原子的甲基, ’二氟甲基或三氟甲基;作為一基或—基之部份的多 i-Γ n· -1— I—I (請先閲讀背面之注意事項再填寫本頁) 基係絲終❹„取代之U基,例 1個:音素曱基中之之基,U_二氟乙基等。當多於 個鹵素原子連接到多鹵素甲基或多齒素 之烧基時,其可為相同或不同。 ^基疋義中
Het係指包括所有於此定義中提及之雜環的可能異 構型式’例如,吡咯基亦包括2H-吼咯基。 、Het基可經由任何適當的環破或雜原子而連接到式⑴ 或(I-a)分子殘基上。因此,例如,當雜料^基時,其 可為2-吡啶基,3_吡啶基或4_吡啶基。 訂 當任何變數(例如,芳基,^^等他任何結構中出 現大於一次時,每一個定義係獨立的。 當線由取代基拉到環系中時,係指該鍵可連接到任何 適當的環原子上。 有些式(IMl(Ia)化合物及其N-氧化物,加成鹽類,季 胺及立體化學異構型式中可含有一或多個對掌中心且以立 體化學異構型式存在。 經濟部智慧財產局員工消費合作社印製 •前文中所使用之“立體化學異構型式,,一詞係定義為 式⑴或(I-a)化合物’及其N-氧化物,加成鹽類,季胺或生 理性官能衍生物可具有之所可能的立體異構型式。除非另 有提及或指示,化合物之化學標準型係為所有可能之立體 化學異構型式之混合物,該含有式(I)或(I-a)化合物及其 N-氧化物,鹽類,溶劑合物或季胺之基本分子結構式以及 -12- 1238161 A7
經濟部智慧財產局員工消費合作社印製 有非對映立體異構物及對映結構體的混 5%从杜、U異構物,亦即含量少於1〇%,以少於 〇的Λ,以少於2%為最佳且以少於1%為特別佳。特 、,立體結構體中心可具有尺_或s_構型 、 份)飽和基上之取代基可具有順式_或反式·構 之化合物在該雙鍵上可具有E<z_立體化學^有= 化合物之讀化學異構型式誠意欲包括在本發明 了/°療之用途,該式(1)或㈣化合物之鹽類為那些 :平衡離子巧藥上可接受的。然而,Μ製藥上可接 又之S夂及驗的細亦發現可,例如,用於製藥上可接受之 化合物的製備或純化。所有的_無論屬於或不屬於製藥 上可接叉者,均包含在本發明之範圍内。 上述製藥上可接受之酸及鹼加成鹽類係包括式⑴或(工_ a)化合物可以形成之治療活性無毒之酸及鹼加成鹽型式。 製藥上可接受的酸加成鹽類可容易地藉著用適當的酸處理 驗型式而得到。適當的酸包括,例如,無機酸,如氫卤 酸,如氫氯酸或氫溴酸,硫酸,硝酸,磷酸等;或有機 酸,例如,醋酸,丙酸,羥基醋酸,乳酸,丙酮酸,草酸 (亦即,乙一酸),丙二酸,琥珀酸(亦即,丁二酸),順式 丁烯二酸,反式丁烯二酸,蘋果酸,酒石酸,檸檬酸,甲 烷磺酸,乙烷磺酸,苯磺酸,對甲苯磺酸,環己氨磺酸, 水楊酸,對胺基水揚酸,棕櫚酸等。 相反的,該鹽型式可藉著用適當的驗處理而轉化為游 -13- 本紙張尺度適用中國國家襟準(CNS ) A4規格(210X297公釐)
1238161 經濟部智慧財產局員工消費合作社印製 Α7 Β7 五、發明説明(12 ) 離鹼型式。 含有一酸性質子之式(I)或(Ι-a)化合物亦可藉著用適當 有機及無機鹼處理而轉化為其無毒之金屬或胺加成鹽型 式。適當的驗鹽型式包括,例如,錄鹽,驗金屬及鹼土金 屬鹽類,如,鋰,鈉,鉀,鎂,鈣等之鹽類,與有機鹼之 鹽類,如,優卡因,N-甲基-D-還原葡糖胺,羥基胺鹽 類,以及與胺基酸之鹽類,例如,精胺酸,離胺酸等。 前文中所使用之加成鹽一詞亦包括式(I)或(I-a)化合物 以及其鹽類可以形成的溶劑合物。此等溶劑合物例如為水 合物、醇化物等。 一些式(I)或(I-a)化合物亦可以其互變異構型式存在。 雖然沒有很明確的在上述化學式中指明,此等型式意欲涵 蓋於本發明之範圍内。 於下文中,“式(I)化合物”或“式(I-a)化合物”一詞 亦包括N-氧化物,加成鹽類,季胺及所有立體異構型 式。 和 特別的化合物包括那些式(I)化合物,其中,R1為氫, 芳基,甲醯基,CV6烷基羰基,CV6烷基,cv6烷氧基羰 基被曱醯基,cv6烷基羰基,cN6烷氧羰基取代之(^.6烷 基。 其他特別的化合物包括那些式(I)化合物,其中係採用 一或多項下列限定: i) -a^akaka4-為式(a-1)之基; R1為氫; -14- ^氏張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐 (請先閲讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 1238161 五、發明说明(13 ) iii) η 為 1 ; iv) R2為氰基,宜位於相許於_NR1_S之對位位置; V) Y為氰基,-C(=〇)呵或-齒素,宜為函素; vi) Q為氫或_NR4R5,其中R4及R5宜為氫; vii) L為柳’其中X宜為NRl,〇或s,x最好為 NH’且R3為以Cl 6燒基,_素及氰基屬較佳取代基 之經取代的苯基。 另外其他特別的化合物包括那些式㈣化合物,其中 R1為氫,芳基,甲醢基,C〗&烷其裝f A ρ ^ “6反I妓基,cv6烷基,cv6烷 氧基獄基,被曱醯基,Cl6炫其雜装 ^ ;;丨·6况暴叛基,Cw烷氧羰基取代 之Cp6烧基。 其他特別的化合物亦包括那些式㈣化合物,其中係 採用一或多項下列限定: μ i) 七1=1)2-(3(1^)斗3七4=為式(b_i)之基; ii) a 為 0 ; iii) R2aS 氰基或-C(=0)NH2,R2a 宜為氰基· iv) Y為氰基’ -C(=0)NH2或鹵素,宜為齒素· v) Q為氫或-NR4R5,其中R4&R5宜為氣; vi) L為-X-R3,其中X宜為NRi,〇或s,χ最好為nh, 且R3為以CV6&基,鹵素及氰基屬較佳取代基之經取 代的苯基。 令人感興趣之化合物為那些式(1)或(1_3)化合物,其 中,L為-X-R3,其中,R3為2,4,6-三取代之苯基,每一個 取代基係獨立地選自氣、溴、氟、氰基或Cl烧美。 -15- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) hL—L---^——0^-------1T------0 (請先閲讀背面之注意事項再填寫本頁) 1238161 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(14 ) 亦令人感興趣者為那些式⑴或(Ι-a)化合物,其中,Y 為氣或溴且Q為氫或胺基。 特別的化合物為那些式(I)或(I-a)化合物,其中位於嘧 。定壤上2-位置之部份為4-氣基-苯胺基。 較佳之化合物為那些式(I)或(I-a)化合物,其中,位於 嘧啶環上2-位置之部份為4-氰基-苯胺基,L為-X-R3,其 中,R3為2,4,6-三取代之苯基,Y為鹵素且Q為氳或 NH2〇 最佳之化合物為: 4-[[4-胺基-5-氯-6-[(2,4,6-三甲基苯基)胺基]-2-嘧啶基]胺基] 苄腈; 4-[[5-氯-4-[(2,4,6-三甲基苯基)胺基]-2-嘧啶基]胺基]苄腈; 4-[[5- >臭-4-(4-氰基-2,6-二甲基苯氧基)-2- ^密ϋ定基]胺基]卞 月f ; 4-[[4-胺基-5-氣-6-[(4-鼠基-2,6-二曱基苯基)胺基]定基] 胺基]苄腈;# 4-[[5 - >臭-6-[(4-氣基-2,6-二甲基苯基)胺基]-2-ΰ密σ定基]胺基] 苄腈; 4-[[4-胺基-5-氣-6-(4-鼠基-2,6-二曱基苯乳基)-2-^σ定基]胺 基]苄腈;及 4-[[4-胺基-5->臭-6-(4-氣基-2,6-二甲基苯乳基定基]胺 基]苄腈;其Ν-氧化物,加成鹽類,季胺及立體化學異構 型式。 通常,式(I-a)化合物可藉著將式(II)中間體,其中W1 -16- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) l·—丨^I丨丨^-IΨ丨丨 (請先閲讀背面之注意事項再填寫本頁)
、1T 1238161 五、 經濟部智慧財產局員工消費合作社印製
L. /N, Y
Q (Π) A7 B7 發明説明(15 ) 為一適當的釋離基,例如,齒素,羥基,三氟甲烷磺酸 鹽,曱苯磺酸鹽,硫代甲基,甲基磺醯基,三氟甲基磺醯 基等,與式(III)胺基衍生物選擇地在不含溶劑條件下或於 一反應惰性溶劑中,例如,乙醇,丨_甲基_2_吡咯烷酮, N,N-二甲基甲醯胺,1,4-二啐烧,四氫呋喃,二甲亞石風, 萘滿,硫烷,乙腈等中,在一反應惰性氛圍中,例如不含 氧氣之氬氣或鼠氣中,且選擇地在一酸,例如,於二乙醚 中之1N氫氣酸等存在之下進行反應而製得。此反應可在 50°C及250°C之溫度範圍間進行。
於此反應及下列之製備法中,反應產物可由反應介質 中單離出來且,如果需要,進一步根據技藝已知之一般方 法純化,例如,萃取法,結晶法,蒸餾法,碾製法及色層 分離法。 式(I-a)化合物,其中L為式-NRl_R3之基,此化合物 以式(Ι-a-l)代表,可藉著將式(IV)中間體,其中,W2為一 適當的釋離基,例如,鹵素或三氟曱烷磺酸鹽,與式(V) 中間體,在不含溶劑之條件下或於一適當溶劑中,例如, 乙醇,1-曱基-2-吡咯烷酮,n,N-二曱基甲醯胺,1 4_ 一 # , 卩亏 烷,四氫呋喃,二曱亞砜,萘滿,硫烷,乙腈等中,在一 -17· 本紙張尺度適用中國國家榡準(CNS )八4规格f (請先閱讀背面之注意事項再填寫本頁)
1238161
五、 發明説明(I6
Q (IV) 經濟部智慧財產局員工消費合作社印製 (VI)
反應-惰性氛圍中,例如不含氧氣之氫氣或氮氣中,且選 擇地在一酸,例如,於二乙醚中之1N氫氯酸等存在之下 進行反應而製得。此反應可在50°C及250°C之溫度範圍間 進行。
式(I-a)化合物,其中L為式-0-R3,此化合物以式(I-a一 2)代表,可藉著將式(IV)中間體,其中,W2為一適當的釋 離基’例如,鹵素或三氟甲炫績酸鹽,與式(VI)中間體, 在一適當溶劑中,例如,1,4-二啐烷,二甲亞砜,萘滿, 硫烷等中,在一反應-惰性氛圍中,例如,不含氧氣之氬 氣或氮氣中,且在一驗,例如,氫化鈉,氫化卸,氫氧化 鈉4存在之下,進行反應而製得。此反應可在5〇它及25〇。〇 之溫度範圍間進行。 V R2a
Q (IV) 式(I-a)化合物可進一步根據技藝已知之轉化反應藉著 將式(I-a)化合物互相轉化而製得。 .18· 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)
1238161 發明説明(η 式(I-a)化合物可根據技藝已 N-氧化物型式之步驟而轉化^目同之n將三價氮轉化為 N-氧化反應通常可藉著將式㈣起始^化物型式。該 機過氧化物進行反應而進行。適當的無機Γ適當有機或無 例如過氧化氫,鹼金屬< 過氧化物包括, 化納·鉀,,過氧 過氧酸㈣取代之笨幾過氧酸:過::笨: ,酸,過烧酸,如過醋酸,燒基氫過氧化物,如乳= 2=乳化物。適當的溶劑為’例如,7卜低級醇類, ’二’經類,如f笨’酮類,如2-丁_,_化烴類, 如,二氣甲烷,及此等溶劑之混合物。 、=如式(I-a)化合物,其中,Q為函素,可用簡2R4 作為試劑,在—反應惰性溶射,例& 1,4_二$燒等,選 擇地在-適,例如三乙胺或N,N二異丙基乙基胺等存 在之下,轉化為相關之化合物,其中Q為-NR4H。當R4含 有經基部份時,亦可輕易地進行採保護型式之NH2R4的反 應,其中之羥基部份攜有一適當的保護基p,其例如可為 一二烷基矽烷基,且隨即根據技藝已知之方法移除該保護 基 經濟部智慧財產局員工消費合作社印製 〇 本發明中之一些式(I_a)化合物及一些中間體可含有 對稱碳原子。該化合物及該中間體之純的立體化學異構型 式可藉著使用技藝己知之步驟得到。例如,非對映立體異 構物可藉物理方法分離,例如,選擇性結晶法或色層分離 技術’例如,逆流分佈法,液體色層分離法等。對映結構 -19- 本紙張尺度適用中國國家標準(CNS ) M規格(21〇χ297公董) 1238161
經濟部智慧財產局員工消費合作社印製 ㈣合物中藉著先將該外消麵合物用適當的 解析餐例如,對掌酸,轉化為非對 合物;然後將該非對映立體異構鹽或化合物之混合;2 例如,選擇性結晶法或色層分離技術,例如,液體色層八 行物理性分離;且最後將該分離出之非對映:: 異構孤或化合物轉化為相關之對映結構體而獲得。純的立 體化學異構型式亦可由純的立體化學異構型式之適當中間 體及起始物f製得,倘若職人反麟立體有擇性發生。 分離式(I-a)化合物及中間體之對映結構體型式的替代 方式包括液體色層分離法,特別是使用對掌性固定相之液 體色層分離法。 些中間體及起始物質為已知之化合物且為市售可得 者或可依據技藝已知之步驟製得。 式(II)中間體,其中L為-X-R3,該中間體以式(11-1)代 表,可藉著將式(VII)之嘧啶衍生物,其中每一個w!定義 如前,與HXR3(VIII)在一反應惰性溶劑中,例如,丨,冬二 σ号烧,2-丙醇等,且在一驗,例如,三乙胺或n,n_二異丙 基乙基胺等存在之下進行反應而製得。可形成不同的專一 區域異構體且可用適當的分離技術,例如,色層分離法, 而由另一個分離出來。
(ΥΙΠ) -20- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公羡) II------II (請先閱讀背面之注意事項再填寫本頁) 訂 R3-
N、 Y
Q (Π-1) 1238161
五、 發明説明(19 式(IV)中間體可藉著將式(VII_a)中間體,其中,W2為 一適當釋離基,例如,鹵素,與式(IX)中間體在一適當溶 劑中,例如,1-曱基-2-吡咯烷酮,1,4-二噚烷等,在一 酸,例如於二乙醚中之1N氫氣酸存在之下進行反應而製 得。此反應可在50°C及250°C之溫度範圍間進行。
(Vn-a) (IX) 替代的,式(IV)中間體可藉著將式(x)中間體與磷醯 氣,三氟甲烧石黃酸酐或其官能性衍生物在一反應惰性氛圍 中,例如不含氧氣之氬氣或氮氣中進行反應而製得。此反 應可在20°c及150°c之溫度範圍間進行。 (請先閲讀背面之注意事項再填寫本頁) 警衣.
⑻ (IV) 經濟部智慧財產局員工消費合作社印製 式(X)中間體可藉著將式(XI)中間體或其官能性衍生物 與式(IX)中間體進行反應而製得。此反應可在無溶劑條件 下或在一適當溶劑中,例如,二甘咪(digiyme),萘滿等, 於一反應-惰性氛圍中,例如不含氧氣之氬氣或氮氣中, 且選擇地在一驗,例如氫化鈉,氫化鉀等存在之下進行。 -21- ‘ 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X297公釐) 1238161 A7 B7 五、發明説明(20 ) 此反應可在100°C及250°C之溫度範圍間進行。
式(X)中間體亦可藉著將式(XII)中間體,其中W2為一 適當釋離基且Y及Q定義如式(I-a)中者,與式(XIII)中間 體在一適當溶劑中,例如乙醇等,及在一鹼,例如乙醇鈉 等存在之下,在一反應-惰性氛圍中,例如不含氧氣之氬 氣或氮氣中進行反應而製得。此反應可在20°C及125°C之 溫度範圍間進行。
(請先閱讀背面之注意事項再填寫本頁) 警衣. 訂 經濟部智慧財產局員工消費合作社印製 一種製備式(IV)中間體,其中Y為溴或氣原子,該中 間體π式(IV-1)代表,之簡易方法包括將溴或氣原子導引 入式(XIV)中間體,其中W2定義如前,其係用Ν-溴琥珀 醯亞胺或Ν-氣琥珀醯亞胺於一反應-惰性溶劑中,例如氣 仿,四氯化碳等中進行。此反應可在20°C及125°C之溫度 範圍間進行。 -22- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐)* 1238161 A7 B7 五、發明説明(u)
(XIV)
(R2)q
b3 R23 (請先閲讀背面之注意事項再填寫本頁) 類似於式(I-a)化合物,其中Q為鹵素,轉化為式(I-a) 化合物,其中Q為-NHR4之反應,式(II),(IV)及(VII) 中間體亦可轉化。 經濟部智慧財產局員工消費合作社印製 依前文所述製法製得之式(I-a)化合物可以立體異構型 式之混合物合成,特別是以可由另一個根據技藝已知之解 析步驟分離之對映結構體的外消旋混合物型式。式(I-a)化 合物之外消旋化合物可藉著與通當的對掌酸進行反應而轉 化為相關的非對映立體異構物鹽型式。該非對映立體異構 物鹽型式則隨即藉者,例如,選擇性或分級結晶法而分離 且對映結構體則藉者鹼而由其間釋出。式(I-a)化合物對映 結構體之分離的代替方式包括用對掌固定相之液體色層分 離法。該純的立體化學異構型式亦可由相關之適當起始物 質之純立體化學異構型式衍生出來,倘若反應係以立體有 擇性發生。如果想要特定之立體異構物,該化合物宜藉立 體有擇之製備方法合成。這些方法以使用對映結構之純起 始物質為有利的。 那些精於此方面技藝之人士將會樂見於上述製法中, 中間體化合物之官能基需要被保護基保護。 需要被保護之官能基包括羥基,胺基及羧酸。羥基之 -23- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部智慧財產局員工消費合作社印製 1238161 A7 _____B7 五、發明説明(22 ) 適當的保護基包括三烷基矽烷基(例如,第三丁基二甲基 矽烷基,第三丁基二苯基矽烷基或三甲基矽烷基),苄基 及四氫哌喃基。胺基之適當的保護基包括第三丁氧羰基或 苄氧羰基。羧酸之適當的保護基包括(^_6烷基或苄基酯。 官能基之保護及去保護可在反應步驟之前或之後進 行。 保護基之使用係完整的敘述於“有機化學之保護 基 ’ JW,F McOmie 編輯,Plenum Press(1973),及“於 有機合成中之保護基”第二版,TW Greene及PGM Wutz Wiley Interscience( 1991) 〇 ι ; 式(I)及(I-a)化合物顯示出抗逆轉錄病毒特性,特別是 抗人類免疫缺乏病毒(HIV),其為人類後天免疫缺乏徵候 群(AIDS)之病原。該HIV病毒首先感染人類T-4細胞且破 壞它們或改變其正常功能,特別是免疫系統的協調作用。 結果’被感染的病患具有非常少的T-4細胞數目,其亦表 現不正常。,免疫性防衛系統不能對抗感染及腫瘤且 被HIV感染之個體通常會因趁機之感染,例如,肺炎,或 因癌症而死亡。其餘伴隨著HIv感染之情況包括血小板減 少症· ’克氏(Kaposi’s)肉瘤及以進行性脫髓鞘作為特徵之中 樞神經系統感染,造成了癡呆及例如,進行性發音不良, 共濟失調及定向力障礙等徵候。HIV感染亦伴隨著末稍神 經病變,進行性全身性淋巴腺病(PGL)及AIDS-相關徵候 群(ARC) 〇 ' 本發明化合物亦顯示出對抗HIV-1株之活性,該株對 -24· 本紙張尺度適用中-__- (請先閱讀背面之注意事項再填寫本頁,>
1238161
五、發明説明(23
科你'已知之非核菩逆轉錄酶抑制劑具有後天的抗性。其 ' 酸糖蛋自亦具很小或不具有結合親合性。 、豆^於其抗逆轉錄病毒特性,特別是其抗_mv特性, 抗-HIV七活性,式⑴或㈣化合物,其队氧化 口 /藥上可接受的加成鹽類,季胺及立體化學異構型式 可用來治療HIV之個別感染及用來預防這些感染。通常, 本發明化合物可用來治療被病毒(其存在储酵素逆轉錄 酶傳’I或依據其者)感染之溫血動物。可用本發明化合物· 來避免^治療之情況,尤其是伴隨著HIV及其他病原性逆 轉錄病骨之情況,包括AIDS,AIDS·相關徵候群(ARC), ^丁 II全身性淋巴腺病(pgl卜以及由逆轉錄病毒造成之 W生CNS疾病,例如,HIV傳介之癡呆及多發性硬化。 ^發明化合物或其任何副族因此與用作為對抗上述情 況醫藥品。該醫藥品之用途或治療之方法包括將有效之 劑置系統性的給藥到HIV-感染之個體以對抗與HIV及其 他病原性逆躺病毒,尤其是與HIV-1有關聯之情況。 •本發明化合物或其任何副族可調配成為各種給藥目的 之製藥型式。它們可以引用通常使用於全身性給藥之藥劑 的所.有組成物作為適當的組成物。於製備本發明之製藥組 成物時,將有效量之作為活性成份的特定化合物,選擇的 以加成鹽型式,與製藥上可接受的載體一起結合到緊密摻 合物中,該載體可根據所欲給藥之製劑的型式而為多種型 式。此等製藥組成物宜為適用於經口,經直腸,經皮,或 非經腸胃注射給藥之單一劑量型式。例如,於製備口服劑 -25- 本紙張尺度適用中國國家標隼(CNS )从規格(21Qx29p^^ " ' — (請先閲讀背面之注意事項再填寫本頁) 訂 0 ί — -1— m · 1238161 A7 B7 五、發明説明(24 經濟部智慧財產局員工消費合作社印製 量型式之組成物時,f使用任何一般的製筚介晳 丨貝,於口服 液態製劑如懸浮液,糠漿,酏劑,乳濁液及溶液之情3 可使用,如水、乙二醇、油類、醇類等;或於粉劑、= 丸、膠囊、及錠劑之情形時,可使用固態載體, 二 粉、糖類、高嶺土、稀釋劑、潤滑劑、黏合劑、崩散劑 等。由於其易於給藥,錠劑及膠囊代表最有利的口服劑I 單位型式,於此情形時,顯然係使用固態製藥載體。於= 經腸胃用之組成物時,載體一般包含無菌水,至少為大部-份,雖然亦可含有其他組份以例如幫助溶解。例如,可製 備注射用溶液,其中載體包含食鹽水溶液,葡萄糖溶液或 食鹽水及葡萄糖溶液之混合物。亦可製備注射用懸浮液, 於此情形時係使用適當的液態載體,懸浮劑等。亦可包含 的為固態型式製劑,其將於使用前轉化為液態型式製劑。 於適用於經皮給藥之組成物中,載體選擇地包含一滲透促 進劑及/或適當的潤濕劑,選擇地包含少量之任何性質的 適當添加劑,-該添加劑不會在皮膚上造成顯著的有害效 應。該添加劑可幫助給藥至皮膚及/或有助於製備所要的 組成物。此等組成物可以藉多種途徑給藥,例如,皮膚貼 布,•點片,軟膏。 為了幫助式(I-a)化合物之溶解,組成物中可包含適當 的組份,例如,環糊精。適當的環糊精為α -,/5 -,τ-環 糊精或醚類及其混合之醚類,其中環糊精之無水葡萄糖單 位之一或多個羥基被下列所取代:Cw烷基,特別是甲 基,乙基或異丙基,如隨意甲基化之/3-CD ;羥基C!·6烷 -26- 本紙張尺度適用中國國^^^( CNS ) A4規格(21Gx297讀^ 一 "" (請先閱讀背面之注意事項再填寫本頁) ί壯衣· -訂· .4 1238161 經濟部智慧財產局員工消費合作社印製 、發明説明(: 基,特別是羥基乙基,羥基丙基或羥基丁基;羧基C16烷 基,特別是羧基甲基或羧基乙基,烷基羰基,特別是 乙&&基。尤其值得注意作為絡合物及/或增溶劑的為冷_ CD,隨意甲基化之石-cd,2,6_二甲基,2_羥基乙 基-/3-CD,2-羥基乙基,2_羥基丙基_T_CD及(2_羧 基曱氧基)丙基-召-CD,且特別為2_羥基丙 冷-CD)。 此合之醚一詞為環糊精衍生物,其中至少兩個環糊精 經基被不同的基,例如羥基丙基及羥基乙基所醚化。 ^ f均莫耳取代(M.S)係用作為每莫耳無水葡萄糖之烷 ^基單位之平均莫耳數的量度單位。平均取代程度(D.S)係 才曰每,水葡萄糖單位之經取代羥基的平均數。m s•及d s. 值可籍多種分析技術例如,核磁共振(NMR),質譜法(紙) 、、、外光%學(IR)來測定。根據所使用之技術,每一給定 的環糊精衍生物可得到稍許不同的值。藉質譜法測量時, 以M.s.範圍(U25至10且D s·範圍〇125至3為宜。 =經口或經直腸給藥之適當組成物包括顆粒物,其 =者將包含式㈣化合物及一適當水可溶性聚合物之混 5贿融擠壓且隨即賴㈣擠壓之混合物灿。缺後該 =粒可藉習用技藝調配成製藥劑量型式,例如錠劑及膠 該難包含—I態分散體,其含有式(ΐϋ及一 或夕種製藥上可接受的水人 口 之較件枯蓺&6X 了/合陡水0物。製備固態分散體 之从技藝為包含下列步驟之熔融-擠屢法·· -27- 冰張尺颜财關家規格(11^— —-L---:----:--衣-- (請先閲讀背面之注意事項再填寫本頁) 訂 --. • 1— I I I I -
1- I 1238161
、發明説明(26 經濟部智慧財產局員工消費合作社印製 a) 將式㈣化合物及-適當切溶性聚合物混合, b) 選擇地將添加物與如此得到的混合物換合, c) 將如此得到的摻合物加熱直到得到—均勻祕融物, 句將如此得到的炼融物強壓通過一或多個喷嘴;及 e)將炼融物冷却直到其固化。 將固恶分散產物碾磨或磨碎成具有小於1500μιη粒子 尺寸之顆粒,宜為小於4〇〇μιη,尤其是小於25〇^m且最 好是小於125μηι。 顆粒中之水可溶性聚合物當其於20°C以2%(w/v)溶解 於水性溶液時具有1至5〇〇mPa s·,尤其是1至 7〇〇mPa.s· ’且特別是1至100mPas·之表現黏度。例如, 適當的水可溶性聚合物包括烷基纖維素,羥基烷基纖維 素,备基烧基烧基纖維素,叛基烧基纖維素,幾基烧基纖 維素之鹼金屬鹽類,羧基烷基烷基纖維素,羧基烷基纖維 素酯,澱粉,果膠,甲殼質衍生物,多糖類,聚丙烯酸及 其鹽類’聚甲雀丙烯酸及其鹽類及酯類,甲基丙浠酸酯共 聚物,聚乙烯基醇,聚伸烷基氧化物及乙烯化氧及丙稀化 氧之共聚物。較佳之水可溶性聚合物為Eudragit E®(;ll0hm GmbH,Germany)及羥基丙基甲基纖維素。 亦有一或多種如揭示於WO 97/18839中之環糊精可於 製備上述顆粒中用作為水可溶性聚合物。該環糊精包括技 藝已知之製藥上可接受的未經取代及經取代之環糊精,特 別是α,沒或τ環糊精或其製藥上可接受的衍生物。 可使用之經取代的環糊精包括揭示於美國專利 -28- 本紙張尺度適用中國國家標準(CNS ) A4規格(21 OX297公釐) (請先閱讀背面之注意事項再填寫本頁) 一裝· -訂 d 五、發明説明(27 經濟部智慧財產局員工消費合作社印製 1238161 二二醚類。另外經取代之環糊精為醚類,其中, =夕個__基之氫被Cl.6燒基,經基Q烧基,叛 ^“6烧基或氧基縣Clj基所取代或其混合之 負特別疋此等經取代之環糊精為鍵類,|中一或多個 =糊精經基之氫被Cl.3烧基,織c24烧基餘基c】_2烧 基所取代’特別是被曱基’乙基,«乙基,祕丙基, 經基丁基,羧基甲基或羧基乙基所取代。 特別有用者為/3-環糊精_,例如,ά M· N〇gradi (198=於 Drugs of the F咖e,v〇1 9, % 8,第 aw 頁 中所沉明之二曱基-沒-環糊精及聚醚類,例如,羥基丙基 万環糊精及私基乙基石-環糊精。此等烧基醚可為一取代 程度為約0.125至3,例如,約〇·3至2之甲基_。此等經 基丙基環糊精可例如由/5 _環糊精及氧化丙烯間之反應形 成且具有約0.125至10 ’例如約〇·3至3之MS值。 另一新穎型式之經取代的環糊精為磺酸基環糊精。 式(I-a)化合物與環糊精之比值可有很大變化。例如, 比值可為1/100至100/1。較令人感興趣之式(I_a)化合物與 環糊精之比值範圍為約1/10至1〇/1。更令人感興趣之比 值範·圍為約1/5至5/1。 亦可方便地將式(I-a)化合物配製成小顆粒型式,其具 有表面改良劑以足以維持小於lOOOnm之有效平均顆粒的 量吸附在其表面上。一般相信有用的表面改良劑係包括那 些物理性吸附在式(I-a)化合物表面而非化學性鍵結至該化 合物。 -29- 本紙張尺度適用中國國家標準(CNS ) Μ規格(2i0><297公董 (請先閲讀背面之注意事項再填寫本頁)
1238161 A7 -—_______B7 五、發明説明(28 ) 適當的表面改良劑宜選自已知之有機及無機製藥賦形 劑。此等賦形劑包括括各種聚合物,低分子量之齊聚物, 天然產物及表面活性劑。較佳之表面改良劑包括非離子性 及陰離子性表面活性劑。 仍有其他包含製藥組成物之調配式化合物的有趣 方式’其中式(I-a)化合物係加到親水性聚合物中並將此混 合物當作外套膜而塗敷在許多小球上,因此獲得一可容易 製得且適用來製備供經口給藥之製藥劑量型式。 該小球包括一中央,圖形或球形的核心,一親水性聚 合物々外套膜及式(I_a)化合物及一密封_外套之聚合物層。 適用作為小球中之核心的物質為多支管,倘若該物質 為製藥上可接受的且具有適當的直徑及堅固性。此等物質 之例為聚奋物,無機物質,有機物質,及糖類及其衍生 物。 尤其有利的是將前述製藥組成物調配成單一劑量型式 以便於給藥或•劑量之均質化。此處所用之單一劑量型式係 指適用作為單一劑量之物理性的個別單位,每一單位中含 有經計算可產生所要治療效果之預定質量的活性組份以及 所需1之製藥載體。此等單位劑量型式之例為錠劑(包括劃 線或包埋錠劑),膠囊,藥丸,粉末包,乾膠片,栓劑, 可注射之溶液或懸浮液等,以及其分離之複數包。 那些精於治療HIV-感染者可以由此處所提供之結果 來決定每曰之有效量。通常,預計的每曰有效劑量係由 0.01毫克/公斤體重至50毫克/公斤體重,更佳者為由〇1 -30- 本紙張尺度適用中國國CNS ) A4規格(210X 297公釐1 --- (請先閲讀背面之注意事項再填寫本頁) ΙΦ 項再填、 裝. 經濟部智慧財產局員工消費合作社印製 1238161 A7 ------- B7 五、發明説明(29^"~ ~ — 一' --- 毫克/a斤體重至10毫克/公斤體重。將所需劑量於適當期 門於天中刀一、二、四或多個次劑量給藥亦適合。該次 劑量可以單位劑量型式配製,例如,每單位劑量型式中含 有1至=00毫克,且特別是5至2⑻毫克活性組份。 、給藥之破實劑量及頻率係根據所用式⑴或㈣之特定 化合物7要治療之特定情形,所要治療之情形的嚴重程 度’特定病患之年齡,體重及一般體能狀況以及個體所服 用之其他醫藥而定,如同精於此方面技藝者所熟知。再 者,很顯然的該每日有效劑量可根據所治療的對象之反應 及/或根據醫生處方本發明化合物之評估而降低或增加。 因此,前文所提及之每日有效劑量範圍僅係導引且並非用 來限制本發明之範圍或用途至任何程度。 經濟部智慧財產局員工消費合作社印製 而且’一抗逆轉錄病毒化合物及式⑴或(I-a)化合物之 組合可用作為醫藥品。因此,本發明亦關於含有(a)式(I)或 (I-a)化合物’(b)另一個抗逆轉錄病毒化合物之合併的製劑 產物以同時,^s開或連續的用於抗_HIV治療。不同的藥 物可與製藥上可接受之載體一起合併於一單一製劑中。該 其他抗逆轉錄病毒化合物可為已知之抗逆轉錄病毒化合 物例如’核苷逆轉錄酶抑制劑,如疊氮胸腺嘧咬核苷 (3’-疊氮基-3’·去氧胸腺嘧啶核苷,AZT),二旦辛 (didanosine)(二去氧次黃嗓吟核苷;ddl),若塞提賓 (zalcitabine)(二去氧胞苷,djc)或拉密威定(1&111^出1^)(3丨- 嗔-2’-3’-二去氧胞苷,3TC)等;非-核苷逆轉錄酶抑制劑, 例如’蘇拉明(suramine),戊聚月米(pentamidine),胸腺五 _ -31- T紙張尺度適用中國國家縣Y^NS) M規格(21〇><297么;^~' " 1238161 A7 B7 五、發明説明(3〇 ) 肽,卡坦諾普明(castanospermine),伊發威諾(efavirenz), 葡Ικ糖(石’il isc葡聚糖)’福斯卡尼-納(騰酸曱酸三鈉),尼威 ---^-----*·^裝-- (請先閱讀背面之注意事項再填寫本頁) 拉派(nevirapine)(l 1-環丙基_5,1卜二氫斗曱基_6Η·二吡淀並 [3,2-b : 2’,3’<][1,4]二氮雜箪_6_酮),9-氨基四氫吖咬(四氫 胺基吖啶)等;TIBO(四氫咪唑並[4,5,1咖][1,4]-苯並二氮雜 箪-2(1H)-酮及硫酮)_型式之化合物,例如,⑻_8_氯_ 4,5,6,7-四氫-5-曱基,6-(3-甲基-2- 丁烯基)咪σ坐並[4,5,ι_ jk][l,4]本並一氮雜箪-2-(1Η)-硫酮;α-ΑΡΑ( α ·苯胺基苯 基乙醯胺)型式之化合物,例如,α_[(2_硝基_苯基)胺基]_ 2,6-一氯本-乙隨胺等;ΤΑΤ-抑制劑,例如,rq_5_3335 等;朊酶抑制劑,例如,因頂那微(indinavir),瑞坦微 (Htanovir),史癸那微㈣咖仙士),aBT-378等;或免疫調 節劑,例如,左旋咪唑等。式(1)或(I_a)化合物亦可與其他 式(I)或(I-a)化合物合併。 下列實例係用來闡明本發明。 d 實驗部份 声 A·中間體化合物之製備 實例A1 經濟部智慧財產局員工消費合作社印製 •在氬氣氛圍中進行反應。將一含2,4,6_三甲基苯胺 (0.00461莫耳)於1,4_二啐烷(5毫升)之溶液加到一^5_溴_ 2,4-二氯嘧啶(0·00439莫耳)於丨,‘二畤烷(5毫升)之溶液 中。將反應混合物攪拌並迴流2〇小時。將溶劑蒸發。將 殘質溶解於醋酸乙S旨中,賴和水性碳酸氫鈉溶液,水及 食鹽水清洗,用硫酸鈉乾燥,過濾,並將溶劑蒸發。將殘 •32- 1238161 、發明説明(31 ^藉管柱色層分離法於_上予以純化(洗提液:1:5, 1:2 CH2Cl2 ·己燒^收集兩個純館份並將其溶劑蒸發, L p〇=克(24%)514·氯,N^4,6_三甲基苯基>2』密咬 胺(中間體1)及0.93克(65。/、<: 使、, 兄165/〇)5_>臭-2-氯_N-(2,4,6-三甲基苯 基)-4-嘧啶胺(中間體2)。 ί^Α2 4 4f基I氣1甲基硫代,_56莫耳)及4-胺鮮 月月(0.078料)以熔融物合併且於⑽-綱。〇授拌6小 時。將反應混合物冷却,且隨即用沸騰的⑶必及 CH3CN礙製以得到95%純化合物,將其乾燥,得到 I·27克(33%)4_[(5-氯_4_輕基_2_續咬基)胺基抒腈(中間 體3 ;熔點>300。〇。 b) 蔣POCl/lO *升)加到中間體⑽〇 〇〇28莫耳)中。將燒 幵瓦裝置以一冷凝器並加熱至⑽^達35分鐘。將物質於 冰中驟冷並收集產生的沈澱物且用水(50毫升)清洗。 將樣品乾燥。將其餾份收集起來並將溶劑蒸發,得到 H(4,5-二氯-2-嘧啶基)胺基]午腈(中間體句。 c) 將含中間體(4)(0.0132莫耳)之四氫呋喃(75毫升)及 ei^ci/io毫升)之混合物攪拌15分鐘。將含於二乙醚 (0.0145莫耳)之HC1緩緩加入,且將混合物攪拌5分 鐘。將溶劑於減壓下移除,得到3·98克4_[(4,5_二氣_ 2-¾咬基)胺基]+腈-氫氯化物(中間體5)。 tin A3 a)將2,4,5,6-四氫嘧啶(〇·〇ΐ34莫耳),1,4-二啐烷(3〇毫 (請先閱讀背面之注意事項再填寫本頁〕 、11 d 經濟部智慧財產局員工消費合作社印製 -33- 1238161 A7 ------—___B7 ____ 五、發明説明(32 ) ^-- 升),2,4,6-三甲基苯胺(0.0134莫耳),及n,n二雙(卜甲 基乙基)乙胺_36莫耳)於氬氣中加到一燒瓶内且於 抑授拌16小時。蒸發出溶劑,並將殘質溶解於 CH2C12巾ϋ後藉官柱色層分離法於㊉膠上(洗提液: CH2a2/己烧i/4 ’及1/2)予以純化。收集所要的德份 並將其溶劑蒸發,得到0」5克4,5,6_三氣_义(2,4,6_三 甲基苯基)-2-較胺(中間體6)及3.1S克2,5,6_三氣_N_ (2,4,6-三曱基苯基)-4-嘴咬胺(中間體7) b)將含中間體7(0.00474莫耳)kNH3(2 〇Mk2_丙醇;2〇 毫升)之混合物於一壓力皿中在75-8〇〇c時加熱4〇分 4里。將溫度提咼至110-115X:。將溶劑蒸發以產生185 克殘貝。於125C將樣品與ΝΗ3(0·5Μ於1,4-二口夸烧; 2〇毫升)一起加熱18小時。將溶劑蒸發,得到17克 兩個異構物之混合物,亦即,2,5_二氣以4_(2,4,卜三甲 基苯基Μ,6-嘧啶二胺(中間體8)及5,6-二氯-Ν4-(2,4,6-二曱基苯基)-2,4-σ密咬二胺(中間體9)。 實例Μ a)將一含‘[(丨,‘二氫_4_酮基j嘧啶基)胺基]午腈(〇12 莫耳)於POC13(90毫升)之混合物於氬氣中攪拌並迴流 20分鐘,將反應混合物緩緩的倒到750毫升冰/水 中’並將固體藉過濾法分離。將固體懸浮於500毫升 水中,並將懸浮液之pH藉添加20%NaOH溶液而調整 至中性。再次將固體藉過濾法分離,懸浮於2〇〇毫升 2_丙酮中,並加入1000毫升CH2C12。將混合物加熱直 -34- 今紙诋尺度通州〒國國家榡準(CNS) A4規格( -裝-- (請先閱讀背面之注意事項再填寫本頁)
、T 4 經濟部智慧財產局員工消費合作社印製 1238161 A7 __________ B7 五、發明説明(33 ) ~" 〜 〜- 到所有固體溶解。冷却至室溫後,分離出水性層,並 將有機層乾燥。於藉著過濾法移除乾燥試劑期間,於 濾液中形成一白色固體。再將濾液於冷凍器中冷却, 接著過濾,得到21.38克(77·2%)4-[(4-氣-2-嘧啶基)胺 基]苄腈(中間體10)。 5)將中間體(1〇)(〇.〇〇5莫耳),1-溴-2,5-吼哈11定二_(〇.〇〇6 莫耳)及二氣甲烧(10毫升)合併於一密封管中並於1〇〇 c加熱過夜。將反應混合物冷却至室溫。加入秒膠(2 克),並將溶劑蒸發。將殘質藉閃蒸管柱色層分離法於 矽膠上(洗提液·· ChCl2/己烷9/1)予以純化。收集純 餾份並將溶劑蒸發,得到1·31克(84·5%)4-[(5-溴-4-氯-2-嘧啶基)胺基]苄腈(中間體π)。 實例Α5 於氬氣下將4-胺基-2,5,6-三氯嘧啶(0.08%4莫耳),4一 胺基-苄腈(0.1071莫耳),1-曱基-2-吡咯啶酮(17毫升)及 HC1於二乙; 85.6毫升)加到一燒瓶中。將混合物於 氮氣流中置於130°C之油浴中直到醚用完。另外加入1〇毫 升1-曱基-2-吡咯啶酮。將混合物於145°C氬氣中加熱16 小時。加入1,4-二呤烧。將混合物迴流,冷却,然後過 濾。將濾液蒸發。將固體溶解於2-丙酮中,於矽膠上蒸 發,並收集且將溶劑蒸發,得到1.63克(6.8%)4-[(4-胺基一 5,6-二氣:嘧啶基)胺基]苄腈(中間體12)。 B最終化合物之製備 實例B1 -35- 本紙張尺度適用中國國^$ ( CNS ) A4^(3i〇X297公釐) " '~~" (請先閲讀背面之注意事項再填寫本頁) ¾衣· 訂 經濟部智慧財產局員工消費合作社印製 1238161 五、發明説明(34 a)於氬氣中將越加到裝有令間體⑴(㈣嶋7莫耳 中广α/二乙〇〇麵莫耳)加 : = 發並加…娜毫升)及4_胺 酸氫鈉^解於CH2Cl2 #,用飽和碳 克-色 將油錯埂相HPLC純化。收隼所 ;夕膠上(洗/疋液:〇及2% CH3〇H : CH C1 )予 以=化。收集純館份並將溶劑蒸發,得到0.(^792克 (2_0%)4-[[5_氯_2_[(2,4,6_三甲基苯 基]竿腈(化合物υ。 』*疋基]胺 藉雜色層分縣於鄉洗提液:〇及 =^】斯輯化。收_份並將溶劑 ㈣’仔到0.0044克(1%)4俗漠_2_[(2 4 6_三甲基苯 基)胺基]-扣密啶基]胺基]苄腈(化合物2)。 土 b)將鍵加到裝有中間體2(〇·〇〇285莫耳)之燒瓶中。將 經濟部智慧財產局員工消費合作社印製 廳二乙謎(1Μ; 0·00855莫耳)加到此均勻溶液中。將 溶劑蒸發並加入Μ-二号院(20毫升)。最後,加入4_ 胺鮮_.0_莫耳)及号燒⑴毫升)並將反 應混合物攪拌並迴流數天。將溶劑蒸發, 於CHA中,fflmNa0H清洗,並將溶劑基發。 將殘質溶解於Οί2α2(1()毫升)並將沈崎 乾燥,得到0.15克(i3%m[5^ 4_[(2,4,6_三甲美笨々 -36- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1238161 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(35 ) 胺基]-2-σφσ疋基]胺基]午腊(化合物3)。tMM a)將中間體(8)及中間體(9)[如同於實例A3b中製得者]3:1 之混合物及4-胺基苄腈(0·01422莫耳)於i8〇t壓力槽 中加熱5小時。將樣品於ch2C12及稀NaHC03之間分 佈,於KfO3上乾燥,過濾,並蒸發。將ch3CN攪拌 加入’將產生的沈澱藉過濾法移除。再將濾液藉逆相 HPLC予以純化。收集純餾份並將溶劑蒸發,得到〇17 克4-[[4-胺基_5_氯_6_[(2,4,6-三甲基苯基)胺基]_2_口密啶 基]胺基抒腈三氟醋酸鹽(1:1)(化合物4)。 實例B3 將合於二乙醚之HC1 (1M ; 0.0045莫耳)加到一含中間 體(4)(0·003莫耳)於1,4-二。号烷(5毫升)之懸浮液中,於氬 氣中可岔封管中攪拌。將混合物加熱以蒸發二乙_,並加 入2,4,6-三甲基苯胺(0.009莫耳)。將管子密封,且將反應 混合物加熱到H50°C達12小時。將反應混合物予以冷却至 室溫。連續的加入矽膠(2.2克)及CH3OH(50毫升)。將溶 劑洛發後’將殘質藉閃蒸色層分離法(洗提級度:ch2ci2 : CH3OH : ΝΗ4ΟΗ 99·5 : 0.45 : 0.05 上至 99 : 0.9 : 0.1)予以 純化。收集純餾份並將溶劑蒸發。將殘質乾燥,得到〇 8〇 克(73.4%)4-[[5-氣-4-[(2,4,6-三甲基苯基)胺基]-2-嘧啶基]胺 基]苄腈(化合物5)。 於氬氣下將一含中間體(5)(〇·〇〇25莫耳)及2,6-二溴一4- -37-
(請先閱讀背面之注意事項再填寫本頁) 一裝.
、1T -1% 1238161
甲基苯胺(〇.〇〇75莫耳)於以^夸燒⑽毫升)之混合物於 -密封管中16G°C加熱並攪拌1M、時。將反應混合物藉旋 轉条發法於石夕膠(2·0克)上濃、缩。將物質藉閃蒸色層分離法 (洗提液:1 : 1 己烷:CH2C12 ;純 CH2Cl2 ; 0·5%,1%(1〇% ΝΗ4〇Η於CH3〇H)於CHfl2)予以純化達9〇%純度。再結 日日可知·到0.15克(12·20/〇)4-[[5-氯-4_[(2,6_二溴_4_甲基苯基) 胺基]-2-鳴咬基]胺基]苄腈(化合物; 95%純度)。 實例Β5 經濟部智慧財產局員工消費合作社印製 於氬氣下將NaH (0.0075莫耳;60%於油中之懸浮液) 加到”可密封式管中之含2,4,6-三甲基苯酚(0·0075莫耳) 於1,4-二哼烷(5毫升)之懸浮液中。將混合物攪拌15分 鐘,且加入中間體(4)(0.0025莫耳)。將管子密封,並將混 合物;^熱^ 150°C達15小時。將反應冷却至室溫。加入秒 膠(2·〇克)後,將溶劑蒸發。將殘質藉閃蒸管柱色層分離法 於矽膠上(洗提梯度:CH2C12 ··己烷:9:1上至1〇〇 : 〇 ;然 後 CH2C12 : Nft4OH : 100 ·· 0 : 0 上至 97 : 2.7 : 0.3)予以純 化。收集純餾份並將溶劑蒸發。將殘質乾燥,得到0.73克 (80·2%)4-[[5-氯冬(2,4,6-三曱基苯氧基)-2_。密啶基]胺基]苄 月膏(化合物6)。 實例Β6 a)於氬氣下在一可密封式管子中將NaH,60%於油(0.003 莫耳)中之懸浮液及1-甲基-2-吼洛咬_(3毫升)加到一 含‘羥基-3,5-二甲基苄腈(〇·〇〇3莫耳)於1,4-二呤烷(3 毫升)之懸浮液中。於Η2放出後,加入中間體 -38- 本紙張尺度適用中國$家標準(CNS ) Α4ϋ( 210X297公嫠Ί " (ιιχο.οοι #耳)。將管子密封並將反應混合物加熱至 160C達16小日寸。將混合物冷却至室溫,移到一燒杯 中並用甲醇(20宅升)稀釋。逐滴加入水(2〇〇毫升)。將 水性此合物用CH2Cl2/CH3〇H9〇/l〇(3x3〇〇毫升)萃取。 將有機層分離,乾燥,過濾並吸附在石夕膠上G克)。將 /合』条1並將殘質藉閃蒸管柱色層分離法於#膠上(洗 提液·· CH2C12/CH30H/NH40H 由 100/0/0 至 98/1·8/0·2) 予以純化。收集所要的餾份並將溶劑蒸發。將殘質用 熱CHsCN礙製,過濾出來,然後乾燥,得到0.20克 (47·6%)4|溴邻-氰基.2,6__二甲基苯氧基)_2寺定基] 胺基]苄腈(化合物17)。 b)將正丁基鐘(〇·〇ι〇莫耳)加到一含(卜甲基乙基片丙 胺(0.010莫耳)於四氫吱喃(25〇毫升)之溶液中,於〇。〇 攪拌。攪拌冷却3〇分鐘後,加入化合物(17)(〇 〇〇5莫 耳)將產生的混合物攪拌冷却15分鐘,於該點加入 2-溴乙醇^酯(0·015莫耳)且將溫度上升至室溫並將反 應混合物攪拌16小時,其使得反應完成 50%。用 0.5 經濟部智慧財產局員工消費合作社印製 *升水驟冷,將樣品藉旋轉蒸發法於矽膠上濃縮,且 藉閃蒸色層分離法(Bi〇tage Fiash 40Μ,用〇,0.5, 1%(1〇%於CHsOH之NH4〇H)於CH2C12洗提)予以純 化,得到白色固體,其為丨:丨之起始物質A :產物。 藉製備性HPLC純化法洗提至含1毫莫耳NaHC〇3之 管子進行最後之純化。將凍乾的物質於水/ CHfUl : 1(全部50毫升))提取並分離。將水相用25 •39- 本紙張尺度適用中國國家標準(CNS ) M規格(2丨〇><297公董 1238161 A7 B7 五、發明説明(38 毫升CH2C12再萃取兩次。合併有機層並於硫酸鈉上乾 燥,過濾於65°c真空中旋轉蒸發18小時成為一白色 固體。產量:〇·33克之
(13%,白色固體);熔點 185-190°C(化合物 59)。 經濟部智慧財產局員工消費合作社印製 c)於Ar氣流中反應。將NaH60%(0·00600 莫耳)於四氫 吱喃(2〇毫升)中攪拌。加入化合物(17)(0.00476莫耳) 並將混合物攪拌15分鐘。加入氯甲基-2,2-二甲基丙酸 酯(0.00600莫耳)且將反應混合物於室溫攪拌16小時, 然後授拌並迴流4.5小時,然後冷却。加入四氫吱喃 (20毫升)加入NaH 60%(0·00600莫耳)及氯曱基_22-二 曱基丙酸雙(0.00600莫耳)且將產生的反應混合物攪拌 24小時。將溶劑蒸發。將殘質溶解於ch2ci2中,用水 清洗,且將溶劑蒸發。將殘質藉管桎色層分離法於矽 %上(洗提液:CH2C12/CH30H 100/0 及 99.5/0.5)予以純 化。收集所要的顧份並將溶劑蒸發。將殘質於Giis〇n 上純化。將此餾份由2-丙醇中結晶出來,過濾出來並
本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) —--------^狀衣-- (請先閱讀背面之注意事項再填寫本頁) -訂 4 1238161 Α7 Β7 五、發明説明(39 ) (23.6%,白色固體)(化合物60)。 d)將一含化合物(17)(0.0020莫耳)於四氫呋喃(4〇毫升)之 懸浮液用0.24克NaH成份處理。將起泡的混合物攪拌 2小時以得到嫩黃色懸浮液。製備一含2,2,_氧基雙乙 醯氣(0.020莫耳)於四氫吱喃(1〇毫升)之溶液並於冰浴 中冷却。經由套管,將產生的A/B懸浮液於1〇分鐘期 間逐滴轉移到2,2'·氧基雙乙醢氯之冷溶液中。將混合… 物加溫至室溫並擾拌3天。再加入〇·24克之NaH且於 兩天後將反應於冰浴中冷却且用曱醇(〇.15〇莫耳)及N N-一乙基乙胺(0.150莫耳)之混合物於3〇分鐘期間逐 滴處理。將反應混合物加溫至室溫且於16 ·小時後倒至 醚中且:用飽和NaHC〇3萃取。將水性餾份用醚萃取兩 次且將合併之醚萃出物用水回洗三次且於MgS〇4上乾 燥。濃縮得到2.91克油狀殘質,將之予以逆相製備性 HPLC。將,適當餾份凍乾,得到〇·ΐ6克灰棕色粉末樣 品(14.5%純化產量)(化合物61)。
實例Β7 於氬氣下將中間體12(0.00286莫耳),4-氰基-2,6-二曱 -41· 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -*W%f ---------衣—— 請先閲讀背面之注意事項再填寫本頁) 、-口 Φ 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 1238161 A7 ___ ____B7_· 五、發明説明(4〇 ) 基苯胺(0.00571莫耳),1MHC1於二乙醚(0.00140莫耳)及 1,4-二啐烧(8毫升)加到一壓力槽中。將反應混合物於油浴 中在氮氣流下加熱直到所有的溶劑蒸發出來。加入1-甲基 -2-吼咯啶酮(3毫升),且將反應混合物於220-240°C加熱3 小時。繼續於210-220°C加熱6小時。將殘質溶解於ι,4-二哼烷,蒸發,於CH2C12& 1N及NaOH間分佈,過渡, 用碳酸鉀乾燥有機層並蒸發。將所要的化合物藉製備性逆 相色層分離法予以單離並純化。收集純餾份並將溶劑蒸 發,得到0.0165克(1.1%於凍乾後胺基氣_6_[(‘ 氰基_2,6-二曱基苯基)胺基]-2-嘧啶基]-胺基]苄腈三氟醋酸 鹽(1:1)(化合物19)。 實例B8 將一含有中間體(11)(0.0011莫耳)2,6_二甲基_4_(2_丙 基)苯胺(0.0011莫耳),N,N,N,,N,-四曱基],笑二胺 (〇·〇〇22莫耳)及1M HC丨於醚(2·3毫升)(〇 〇〇^莫耳)τ於1,‘ 二呤烧(25毫升)之混合物搜拌並加熱到%。。達a j時 藉旋轉蒸發法移除溶劑並將殘質藉逆相製備性hplc'B予以 純化。將含有所要物質之合併餾份凍乾,得到〇·23克之
(48%);熔點·· 198-201〇C(化合物)。 -42- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X^97公釐)- IK—I—1^—-------IT------φ (請先閱讀背面之注意事項再填寫本頁) 1238161
、發明説明(4 經濟部智慧財產局員工消費合作社印製 f例B9將N,N-二(甲基乙基)乙胺(0 〇〇24莫耳)加到4•胺基_ 2,5·二甲基-3,4-苄腈(0·00219 莫耳)及 4-[[(5-溴-4,6-二氯) 嘧啶基]胺基]-苄腈(0.00219莫耳)中。將反應瓶密封並攪拌 加熱至155-160°C達1.5天。將樣品冷却至室溫。將樣品 用閃蒸管柱色層分離法於矽膠上(洗提液:CH2C12)處理。 經由製備性HPLC完成純化,得到0β05克4_[[5_溴_4_氯_6_ [(4-氰基-2,6_ 一甲基本基)胺基]_2嘴咬基]胺基]节骑· (5.0%);熔點:259-260。。(化合物 42)。 f 例 Β10 蓮續將2,4,6-三曱基苯胺(ο·,2莫耳)及N,N•二(甲基 乙基)_乙胺(0.0024莫耳)加到一含4_[[5_溴_4,卜二氯]·厶嘧 啶基]胺基〕苄腈(0.00218莫耳)於丨,4_二噚烷(1〇毫升)之 溶液中。將管子密封並將懸浮液於油浴中攪拌加熱至12〇_ 130°C達90小時。將混合物冷却至室溫。再加入况沁二 (甲基乙基)^乙胺(15毫升),並將樣品再加熱至12〇_13〇 C達64小時。將反應於i5(rc加熱6天。將樣品冷却至室 溫。將樣品用醋酸乙酯稀釋並用冷的NaOH萃取。將 水相.用醋酸乙酯回洗。將合併之有機相乾燥並濃縮。於矽 膠上(洗提液:Ci^Cl2)進行閃蒸管柱色層分離。將樣品再 次藉製備性HPLC予以純化,得到〇·53克_4-[[5-溴_4_氯 6-[(2,4,6-三甲基苯基)胺基]-2_,唆基]胺基汗腈(54.9%)、; 熔點·· 220-221。(:(化合物 41)。 實例 (請先閱讀背面之注意事項再填寫本頁) 一裝· 訂 4 -43·
1238161 Α7 Β7 五、發明説明(42 ) 將一含4_胺基苄腈(0.0043莫耳)及
(0皿1莫耳)於1,4_二吟院(3〇毫升)之混合物於授摔 I6小時。將溶劑藉旋轉蒸發法移除。將固體殘質礙製並將 殘質於40°C真空中乾燥16小時,得到〇·452克之
%♦.〇·
I JJ-----0^! (請先閱讀背面之注意事項再填寫本頁) ΝΗ 八
A (55/ί>) ’ 炼點· >300 C (化合物 43)。 實例B12 Λτ°^Λτ 經濟部智慧財產局員工消費合作社印製 將Ν^Ν (0.00567莫耳),4-胺基苄腈 (0.01163莫耳)及1-曱基-2-吡咯啶酮(20毫升)加到一壓力 槽中'將反應混合物於140°C加熱達16小時。將反應混合 物冷却至室溫並加入乙腈及水。將產生的沈殿過濾出來, 並將固體用乙腈再結晶,得到1.27克4-[[5-溴-4-(4-氰基-2,6-二曱基苯氧基)-6-曱基-2-嘧啶基]胺基]苄腈(52);熔 點:260-262°C(化合物 44)。 實例B13 -44· 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 1238161 A7
1238161 Α7 '^^---— Β7 五、發明説明(44 ) ' "—~ - : :-----批衣-- (請先閱讀背面之注意事項再填寫本頁} 比咯啶乙胺(0.00198莫耳)加到一壓力槽中。將混合物於 75°C加熱16小時。加入,並將混合物用水清洗, 乾燥,過濾並將濾液蒸發。藉閃蒸管柱色層分離法用丨:9 之甲醇:二氯甲烷洗提而予以純化,得到一固體,其再溶 解於CH3CN中。加入HC1/二乙醚1·0Μ (0.48毫升),並 將混合物於冰中冷却。過濾得到〇19克4-[[5_溴-4-(4-氰基 -2,6-一甲基苯氧基)-6-[(1_吡咯啶基)乙胺基]_2-嘧啶基]胺基] 午腈氫氣酸鹽(1:1)(50.6%);熔點·· 208-210 °C (化合物 47)。 ° 實例B16 經濟部智慧財產局員工消費合作社印製 將4-[[5-溴-4·(4-氰基-2,6-二甲基苯氧基)_6_氯_2_嘧咬 基]胺基]苄腈(0.00064莫耳),四氫呋喃(3毫升),〇_甲基 备基胺(0.06克),四氫吱喃及NaOH 1N (0.00067莫耳)加 到一壓力槽中。將反應混合物於室溫下攪拌3天,然後於 75t攪拌1天,於90°C攪拌1天且於11〇。(:攪拌2天。將 四氫呋喃(4毫升)及NaOH 50% (0.00719莫耳)加到〇一 曱基羥基胺(0.60克)中。將液體傾析至反應瓶中並將反應 混合物於110°c加熱3天。將溶劑蒸發。將殘質溶解於 CH^Cl2,用飽和NaHC〇3溶液及水清洗,乾燥(Na2S〇4), 過濾並將溶劑蒸發。將殘質藉管柱色層分離法於石夕膠上 (洗提液:CH^C^/Ci^OH 98/2)予以純化。收集純餘份 並將溶劑蒸發。將殘質由CHSCN中結晶出來,過濾出來 並乾燥,得到0.15克4-[[5_溴_4_(4-氰基_2,6_二甲基笨氧 基)_6_ (甲氣基胺基)密σ定基]胺基]+腊(η%);溶 · 本紙張尺度適用中國國家標準(CNS ) Α4規格(210: -46- 1238161 A7 B7 五、發明説明(45 185-186 C。將樣品乾燥(〇·2 mmHg,帆,16小時)(化合 物 48)。 實例B17 a)於0°C時將正-丁基鋰(2 〇毫升,〇 〇〇5莫耳)加到一含卜 (甲基乙基)-2-丙胺(0·70毫升,〇·〇〇5莫耳)及四氫呋喃 (300毫升)之經攪拌的溶液中。攪拌冷却達分鐘 後’加入化合物(17)(〇·〇〇5莫耳)。將產生的混合物攪 拌冷却達30分鐘,於該點加入u-二曱基乙基溴醋酸 酯(1.5毫升,1〇毫莫耳)並將溫度提昇至室溫並將反應 攪拌3小時。於一分開之燒瓶中將正·丁基經(2〇毫 升’ 5莫耳)力口到一含ι_(甲基乙基)_2_丙胺(〇·7〇毫 升’ 5耄莫耳)於四氫吱σ南(5〇毫升)之經搜拌的〇。〇溶 液中,且予以反應30分鐘,於此時其轉化為室溫反 應。重覆此過程。用〇·5毫升Ηθ驟冷,將樣品藉旋 轉蒸發法濃縮至矽膠上,且藉閃蒸色層分離法(用 〇·1〇,20%之於己烷的醋酸乙酯洗提)予以純化,得 到一白色固體之 ▼裝-- (請先閱讀背面之注意事項再填寫本頁) 訂 4 經濟部智慧財產局員工消費合作社印製
熔點:195-197°C (化合物56) b)將一含化合物(17)於40毫升N,N_二曱基曱醯胺之懸浮 -47- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1238161 A7 B7 五、發明説明(46 ) 液用0.24克NaH處理。將起泡的混合物攪拌。製備— 含1,心二氯-1,4-丁二酮於10毫升N,N_二甲基甲酸胺之 溶液且於冰浴中冷却。將由化合物(17)製得之混人物 轉移到1-(甲基乙基)-1-丙胺之冷溶液中並擾拌42小日夺 而溫熱至室溫。再加入〇·24克NaH,將反應授掉3 天,且用醚稀釋並倒至冰中。藉過濾法移除沈殿。將 2相濾液分離並將酸的水性餾份再用醚萃取兩次。將 合併醚餾份用少量的蒸餾水清洗並乾燥。將溶劑蒸發 並將殘質予以矽膠管柱色層分離。逆相製備性 及立即性冷却以凍乾適當餾份,得到0.07克之 -—--------•壯衣-- 一、請先閲讀背面之注意事項再填寫本頁}
-訂 (7·8%);熔點:232-233°C (化合物 57) c)於氬氣下,將NaH 60%及四氫呋喃加到一燒瓶中。將 反應於室溫中授掉10分鐘並加入化合物(17)。搜掉1 小時後加入氯化碳酸乙S旨。將反應混合物於室溫再授 拌16小時並將溶劑蒸發。將殘質部份地溶解於二曱亞 石風中並過濾。將渡液藉逆相色層分離法予以純化並束 乾,得到0.47克(18%)之 (化合物58) -48- 本紙張尺度適用中國國家標準(CNS ) M規格(210x297公釐) d 經濟部智慧財產局員工消費合作社印製
1238161 A7 B7 一五 經濟部智慧財產局員工消費合作社印製 發明说明(47 ) d)將一含有4-[[5-胺基-4-(4-氰基-2,6·二曱基苯氧基)_2_喷 淀基]一胺基]午腈(0.00147莫耳)於醋酸針(1〇毫升)及 2-丙酮(1〇毫升)之混合物於室溫攪拌16小時。然後將 混合物加熱至55°C,且再加入醋酸酐(3毫升)。將混 合物於18小時後由熱源移開並於室溫攪拌6天。將樣 品藉旋轉蒸發法濃縮成一固體。藉管柱色層分離法(用 〇, 0.5,1,1.5, 2%(1〇% ΝΗ40Η 於 CH3OH),於二氣甲 炫,洗提)予以純化’得到 〇
溶點·· 290-295 C。將該固體於60°C真空中乾燥16小 時(化合物49)。 實例B18 - 將一含有4-[[4-(4-氰基-2,6-二甲基苯氧基)-5-硝基_2_ 嘧啶基]胺基]-苄腈(〇力〇〇5莫耳)於四氫呋喃(2〇毫升)之混 合物*用Pd/C ι〇^(〇·ι⑼克)作為催化劑而氮化過夜。吸收 Η2後(3倍量;0.0015莫耳),過濾出催化劑並將濾液藉旋 轉蒸發法濃縮並於40°c真空中乾燥16小時,得到0·15克 4-[[5**胺基-心(4-氰基-2,6-—曱基苯氧基)-2-,。定基]胺基] 腈(84%);溶點:>3〇〇°C(化合物50)。 tiH B19 •49· 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇X297公釐) (請先閲讀背面之注意事項再填寫本頁) I裝· 4 1238161
五、發明説明(48 ) 將4-[[4-[(2,4,6-三甲基苯基)胺基]-5_硝基-2-嘧啶基]胺 基]节腈(0·001莫耳),Pd/C 10% (0.〇25克),乙醇(2〇毫 升)’及肼( 0.030莫耳)合併以形成一生料並於室溫授 掉16小時。將溶劑藉旋轉蒸發法移除。將殘質於四氳吱 °南(20毫升)及曱醇(1毫升)中提取。加入第2份胼 (〇·5克),並將反應於室溫攪拌16小時。加入第3份胼 (〇.5毫升)並將反應於室溫再攪拌16小時。將樣品藉旋 轉蒸發法濃縮至矽膠上(丨克),且藉閃蒸色層分離法 (洗提液:0.5,1.2%,1〇%(NH4OH)於 CH3OH)於 Ct^Cl2)予以純化。將所要的餾份藉製備性hPLc予以純 化’得到0.24克4_[[5_胺基_4_[(2,4,6_三甲基苯基)胺基] 定基]胺基]苄腈(70%);熔點·· 224-225°C(化合物 51)〇 3^1^20 將化合物(3)(0.001莫耳),三甲基矽烷腈(〇〇〇12莫
耳)Pd (PPhAC^ (0·020 克),Cul (0.010 克)及 CF3COOH 經濟部智慧財產局員工消費合作社印製
啦2〇(3毫升)合併於一密封管中並加熱至u〇〇c達1〇小 時。加入第二份的催化劑Pd (PPh3)2Cl2 (〇 〇2〇克)及CuI (〇·01·0克)及CFsCOOH /HP (3毫升)並將反應混合物於 110C攪拌1〇小時。將物質藉旋轉蒸發法濃縮。將殘質藉 製備性逆相製備性HPLC予以純化。將所要的餾份濃縮並 藉逆相HPLC予以純化並用%氣流乾燥,然後於4〇。〇真 空中達16小時。產量:o.ou克之乙炔基-4七2,4,6_ 一甲基本基)胺基]定基]胺基]+腈;溶點:i65-175°C -50· 本紙張尺度適用中國國家標準(CNS ) A4規格(21 〇 χ 297公楚)~------ 1238161 A7 ____ _ B7_ 五、發明説明(49 ) ^ 〜〜〜 (化合物52)。 實例B21 於A下將化合物(3)(0·000906莫耳),三丁基苯基錫酸 酯(stannane)(〇.〇〇〇9〇6 莫耳),Pd (PPh3)4 (0.002718 莫耳), 及1,4-二啐烷(3毫升)合併於一密封管子中並加熱至 110°C達16小時。將反應混合物冷却並藉旋轉蒸發法而濃 縮。將樣品藉製備性逆相HPLC予以純化,然後於Ar氣 流中乾燥,於真空中乾燥,得到〇·〇845克之4-[[5-苯基I, [(2,4,6-二甲基本基)胺基]-2-嘴σ定基]胺基]节膀;溶點: 209-214°C(化合物 53)。 實例B22 於Ar下將化合物(3)(0·001莫耳),四乙烯基錫酸酯 (0.22 毫升)’ 1,4-二哼烧(2 毫升)及 pd(pph3)4(〇」i2 克 合併於一密封管中)。將混合物攪拌並加熱至l〇(rC達 小時。再加入四丁烯基錫酸酯及pd(pph3)4。將反應置於 Ar中,攪拌並加熱。將反應藉旋轉蒸發法濃縮且於製備 性HPLC上純化。將物質用n2氣流乾燥,並於6〇〇c真空 中乾燥4小時,得到0.422克4-[[5-乙烯基-4-[(2,4,6-三甲 基苯•基)胺基嘴啶基]胺基]乎腈;熔點:237-242°C (化合 物 54)。 實例B23 於氬氣中將化合物(3)(0.0(^225莫耳), CuCN(0.001470莫耳)及N,N-二甲基曱醯胺(2毫升)合併於 一岔封管中,然後攪;拌並加熱至16(TC達16小時。將殘質 -51- 本紙張尺度適用中國國家標準(CNS ) A4規格(2ι〇χ^7公慶)--- *·*m i - I-------壯衣 i !, 請先閱讀背面之注意事項再填寫本頁〕 ♦ 經濟部智慧財產局員工消費合作社印製 1238161 A7 B7五、發明説明(5〇 ) 藉管柱色層分離法(洗提液:CH2C12/己烷1/1,然後為純 CH2C12)予以純化。收集所要的餾份並將溶劑蒸發。將殘 質於室溫用CH2C12碾製。將固體乾燥(真空,40°c,24 小時),得到0.0864克之
(24%);熔點:254-259°C(化合物 55)。 表1、2、3及4中所列出之式(I-a)化合物係依類似於 上述實例之一者製備。 請先閱讀背面之注意事_ I# ,項再填· 裝-- _寫本頁) 訂 it 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1238161 A7
7 B 五、發明説明(5l ) 表1 CNa:
化合物 號碼 實例 號碼 Y 物理數據 1 Bla Cl - 2 Bla Br mp. 227-228°C 22 Bll N02 mp. 224-226°C (請先閱讀背面之注意事項再填寫本頁) 表2
Ra
H——N 經濟部智慧財產局員工消費合作社印製
號碼 實例 號碼 Ra Rb Rc X Y Q mp. / 鹽 3 Bib ch3 ch3 ch3 NH Br H mp. 227-228°C 4 B2 ch3 ch3 ch3 NH Cl nh2 mp. 241-242°C; 三氟醋酸鹽(1:1) 5 B3 ch3 ch3 ch3 NH Cl H mp. 224-226°C 6 B5 ch3 ch3 ch3 〇 Cl H mp. 218-219°C 7 B5 ch3 ch3 ch3 S Cl H mp. 264-266°C 8 B5 ch3 Br ch3 〇 Cl H mp. 237-238°C 9 B3 ch3 Br ch3 NH Cl H mp. 217-219°C 10 B4 Br ch3 Br NH Cl H mp. 262-263°C -53- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1238161 五、發明説明(52 ) 經濟部智慧財產局員工消費合作社印製 A7 B7
編號 實例 號碼 Ra Rb Rc X Y Q mp·/ 鹽 11 B4 Br Br F NH Cl H mp. 200-202°C 12 B4 ch3 C(CH3)3 ch3 NH Cl H mp. 214-215°C 13 B4 ch3 CN ch3 NH Cl H mp. 281-283°C 14 B4 Cl Cl ch3 NH Cl H mp. 243-245°C 15 B5 Cl Br ch3 0 Cl H mp. 244-247〇C 16 B5 ch3 Cl ch3 0 Cl H mp. 232-235°C 17 B6 ch3 CN ch3 0 Br H mp. 288-289°C 18 B5 ch3 CN ch3 0 Cl H mp. 283-284°C 19 B7 ch3 CN ch3 NH Cl nh2 mp. 266-268°C; 三氟醋酸鹽 (1:1) 20 B3 Cl Cl ch3 NH Br H mp. 253-254°C 21 B3 ch3 Br ch3 NH Br H mp. 243-245°C 23 B23 ch3 CN ch3 NH CN H mp. 275-290°C; trifluoroacetate (1:1) 24 B23 ch3 Br ch3 NH CN H mp. 291-299°C 25 B14 ch3 CN ch3 0 Br nh-ch3 mp. 248-250°C 26 B14 ch3 CN ch3 0 Br nh2 nh2 mp. 255-256°C 27 B14 ch3 ch3 ch3 〇 Br - 28 B14 ch3 ch3 ch3 〇 Br nh-ch3 mp. 213-214°C 29 B14 ch3 CN ch3 0 Br NH-C2H5 mp. 263-264°C 30 B14 ch3 CN ch3 0 Cl nh2 mp. 272-274°C 31 B14 ch3 ch3 ch3 0 Cl nh2 mp. 199-202°C 32 B11 ch3 ch3 ch3 NH N02 H mp. >300°C 33 B5 ch3 ch3 ch3 0 Br H mp. 207-215°C 34 B5 ch3 ch3 ch3 〇 Cl Cl mp. 225-226°C 35 B5 ch3 CN ch3 0 Cl Cl mp. 273-276°C 36 B6 ch3 CN ch3 0 Cl Br mp. 281-282°C 37 B5 ch3 ch3 ch3 〇 Cl Br mp. 214-215°C 40 B8 ch3 CH(CH3)2 ch3 NH Br H mp. 198°C; 三氟醋酸鹽 (1:2) 41 B10 ch3 ch3 ch3 NH Br Cl mp. 220°C 42 B9 ch3 CN ch3 NH Br Cl mp. 259°C 43 B11 ch3 CN ch3 0 N02 H mp. >300°C 44 B12 ch3 CN ch3 0 Br ch3 mp. 260°C 45 B13 ch3 CN ch3 NH Br H mp. 277°C 46 B14 ch3 CN ch3 0 Br nh2 mp. 255°C (請先閲讀背面之注意事項再填· :寫本頁) -54- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X Μ?公釐) 1238161 A7 B7 五、發明説明(53 ) 經濟部智慧財產局員工消費合作社印製
編號 實例 號碼 Ra Rb Rc X Y Q mp·/ 鹽 47 B15 ch3 CN ch3 0 Br mp. 208°C;HC1 (1:1) 48 B16 ch3 CN ch3 0 Br -nh-o-ch3 mp. 185-186°C 49 B17d ch3 CN ch3 0 -NH-COCH3 H mp. 290-295°C 50 B18 ch3 CN ch3 0 -nh2 H mp. >300°C 51 B18 ch3 ch3 ch3 NH -nh2 H mp. 224-225°C; 三氟醋酸鹽(1:1) 52 B20 ch3 ch3 ch3 NH CN H mp· 165-175°C 53 B21 ch3 ch3 ch3 NH phenyl H mp. 209-214°C 54 B22 ch3 ch3 ch3 NH -ch=ch2 H mp. 237-242°C; 三氟醋酸鹽U) 55 B23 ch3 ch3 ch3 NH -ch=ch2 H mp. 254-259°C 表3
化合物 说碼 實例 號碼 Z 38 B17C -c(=o)-ch3 mp. 194-196 °C 56 B17a •CH2-£:0-0-C(CH3)3 mp. 195-197°C 57 B17b _CH=0 mp. 232-233°C 58 B17c -CO-O-C2H5 mp. 209-210°C 59 B6b -CH2-CO-OC2H5 mp. 185-190oC 60 B6c • -ch2-o-co-c(ch3)3 mp. 168-169°C 61 B6d -CO-CH2-OCH2-CO-OCH3 mp. 184-185°C 表_4
化合物. 號碼 實例 被碼 Ra Rb X Y Q 39 B5 Cl Cl S Br H mp. 198-200 °C -55- 广讀先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1238161 A7 ______ B7 五、發明説明(54 ) C·藥理實例 實例C.1 使用一快速、光敏且自動化之分析過程來進行抗_HIV 试劑之生體外評估。用HIV-1變性之T4-細胞系作為目標 細胞系,其如前所示(Koyanagi等,lnt· j· cancer,也445- 451,1985)為對HIV感染而度易受影響且可接受。對於 HIV-誘發之細胞病變效應的抑制作用係作為終點。mv-感 染及模擬感染細胞兩者之生存能力係用在原處3_(4,5-二甲 基嗔。坐-2-基)-2,5-—本基四α坐銻》臭化物(μττ)之還原作用來 進行分光光度分析。以50%細胞毒性濃度(CC5i),#Μ)定 義為可減少模擬感染控制組樣品吸附50%之化合物濃度。 化合物在HIV-感染細胞上所達到的保護百分比係用下列 程式計算: (OPT)HIV — (OPc)HTV (ODc)mock — (ODc)hiv X /〇表示 經濟部智慧財產局員工消費合作社印製 其中’(ODT)mv係用HIV-感染細胞之測試化合物的給定濃 度所測又之光岔度,(〇Dc)hiv係控制組未經處理之hiV-咸 染細龅所測得的光密度;(ODc)mock係控制組未經處理之 模擬-感染細胞所測得的光密度;所有光密度值係於 540nm測定。根據上述程式,可達到50%保護作用之劑量 係定義為50%抑制濃度(ICw μΜ)。(^(^與圯外之比值係 定義為選擇性指數(SI)。式(Ι-A)化合物顯示出抑制HIV 之功效。特定的IC%,CCw及SI值係列於下表5中。 -56- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1238161 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(55 ) 表5 化細 編號 IC5〇 (μΜ) CC5〇 (μΜ) SI 2 0.030 82.6 2730 3 0.006 4.4 738 1 0.004 10.9 2787 4 0.002 10.0 5555 5 0.002 0.4 178 6 0.009 > 100 > 11049 7 0.084 > 100 > 1182 8 0.012 >100 >8298 9 0.003 1.2 376 46 0.002 >200 >71428 61 0.002 > 100 >52631 化 編號 IC5〇 (μΜ) CC5〇 (μΜ) SI 10 0.005 0.4 92 11 0.002 0.4 183 12 0.020 48.5 2393 13 0.0005 0.4 860 14 0.002 0.4 191 15 0.010 >100 > 9661 16 0.010 >100 >10416 17 0.002 >10 >6451 18 0.001 >10 >7142 60 0.002 74.52 39223 l·^.--^---.--裝-- (請先閲讀背面之注意事項再填寫本頁) 訂 -1¾ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)
Claims (2)
- A8 B8 C8 D8 1238161 六、申請專利範圍 專利申請案第88119614號 ROC Patent Appln. No.88119614 修正後無劃線之申請專利範圍中文修正本一附件(一) Amended Claims in Chinese - Enel, (Ϊ) 5 (民國93年12月扣曰送呈) (Submitted on December ^>〇 5 2004) 1. 一種具下式之化合物、其N-氧化物或加成鹽, 1015 其中 q 為0、1或2 ; R1為氫;曱醯基;C!-6烷基羰基;Cm烷氧基羰基; 經Ci-6烧氧基戴基或Ci-6烧基戴基氧基取代之Ci-4 烷基;經Cw烷氧基羰基取代之Cw烷氧基Cw 20 烷基羰基; R2a為氰基或Cm烷基; 經濟部智慧財產局員工消費合作社印製 每一個R2為CV4烷基; L 為-X-R3,其中 R3為苯基,其經一、二或三個各自獨立選自氰基、 25 鹵素或Cu烷基之取代基所取代;且 X 為-ΝΗ-,-0-,或-S-; Q 代表氫,CV4烷基,鹵素或-NHR4 ; -58 - 88404B-接 1 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1238161 Α8 Β8 C8 D8 六、申請專利範圍 且 R4選自氫,Cw烷基,Cm烷氧基或經吡咯啶基取代 之Ci_6烧基; Y 代表鹵素,氰基,石肖基,胺基,C2-4晞基,
- 5 -NHC(=0)CH3 或苯基; 其限制條件為當R1代表氫,Q代表氫或CN4烷基,及 Y代表鹵素、胺基、硝基、C2_4烯基或-NH-C(=0)CH3 時,則X不為S。 2. 如申請專利範圍第1項之化合物,其中R1為氫,甲醯 10 基,cle6烷基羰基,Cw烷氧基羰基,經Cw烷氧基羰 基取代iCw烷基。 3. 如申請專利範圍第1或2項之化合物,其中R3為2,4,6-三取代之苯基,其中取代基各自獨立選自氰基、鹵素 或Cw烷基。 15 4.如申請專利範圍第1或2項之化合物,其中Y為氰基 或鹵素。 5. 如申請專利範圍第1或2項之化合物,其中Q為氳或 NHR4 〇 經濟部智慧財產局員工消費合作社印製 6. 如申請專利範圍第1項之化合物,其中化合物為4[[4- 20 胺基-5-氣-6_[(2,4,6-三甲基苯基)胺基]-2-嘧啶基]胺基] 苄腈;4-[[5_氯-4-[2,4,6-三甲基苯基]胺基]-2-嘧啶基]胺 基〕卞腊;4-[[5->臭-4-(4-氰基-2,6-二甲基苯氧基)-2-ϋ密 啶基]胺基〕苄腈;4[[4-胺基-5-氯·6-[(4-氰基-2,6-二甲 基苯基)胺基]-2-嘧啶基]胺基]苄腈;4-[[5-溴-6-[(4-氰基 -59 - 本紙張尺度適用中國國家標準(CNS)A4規格(210x297公釐) Β8 C8經濟部智慧財產局員工消費合作社印製 1238161 _2,6-二甲基苯基)胺基〕_2_。密啶基]胺基]节腈;外屮胺 基-5-氣-6-(4-氰基-2,6-二甲基苯氧基)_2_嘧啶基]胺基] 苄腈,或4-[[4-胺基-5-溴-6-(4-氰基-2,6-二甲基苯氧 基)-2-嘧啶基]胺基〕苄腈;其砵氧化物及加成鹽。 5 7·如申請專利範圍第6項之化合物,其中該化合物為 4-[[4_胺基-5_溴-6-(4-氰基-2,6-二甲基苯氧基)_2“密啶 基]胺基]卞腊’其N-氧化物及加成鹽。 8·如申請專利範圍第1、2、ό或7項中任一項之化合物, 其係用於治療HIV感染。 〇 9·如申請專利範圍第1項之化合物,其係用於製備用來 冶療HIV(人類免疫不全病毒)感染之醫藥品。 1〇·如申請專利範圍第9項之化合物,其係用於製備用來 治療對多種藥具抗性之HIV感染的醫藥品。 15 如申叫專利範圍第9項之化合物,其係用於製備用來 治療HIV感染之醫藥品,該ffiv對於如申請專利範圍 第9項之化合物以外的非核苷逆轉錄酶抑制劑具抗性。 12·如中請專利範圍第9項之化合物,其制於製備用來 治療HIV1感染之醫藥品,該Hm對於如巾請專利範 圍第9項之化合物以外的非核苷逆轉錄酶抑制劑具抗 性。 13_如申請專利範圍第卜2、6或7項中任一項之化合物, 其係用於製備絲治療HIV❹的醫藥品。 14·如申請專利範圍第卜^或?項中任一項之化合物, 其係用於製備用來治療對乡種藥具抗性之mv感染 ---—一 —___^ - 60 - 本紙張尺標準規格⑵1238161 A8 B8酋樂品 經濟部智慧財產局員工消費合作社印製 t申”月專利範圍第卜2、6或7項中任_項之化合物, ,、係用於製備用來治療HIV錢之醫藥品,該HIV對 5如申請專利範圍第1、2 ' 6或7項中任-項之化合物 以外的非核菩逆轉錄酶抑制劑具抗性。 如申明專利圍第1、2、6或7項中任-項之化合物, 係用於製備用來治療HIV 1感染之醫藥品,該hivi 對如申請專利範圍第1、2、6或7項中任-項之化合 物以外的非核苷逆轉錄酶抑制劑具抗性。 10 I7· 一種用於治療HIV感染之醫藥組成物,其包含製藥上 可接受的載體及治療活性劑量之如申請專利範圍第工 至7項中任一項之化合物。 一種製備如申請專利範圍第1項之化合物的方法,其 特徵在於 a)使式(II)中間體與式(111)胺基衍生物在無溶劑條件下 或於反應-惰性溶劑如乙醇、1·甲基-2-吡咯啶嗣、N,N-二甲基甲醯胺、1,4-二。等烧、四氫呋喃、二甲基亞石風、 四氫萘、碰醢烧(sulfolane)、乙腈等之中,在反應_ 惰性氛圍如無氧之氬或氮中進行反應 18· 15 20(H)m R1-61 - 紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公爱)1238161 Α8 Β8 C8 D8 六 申請專利乾圍 其中,W1為一適當的釋離基且L,Y,Q,Rl,R2,R2^q 係如申請專利範圍第1項中所定義; b)使式(IV)中間體與式(v)中間體在無溶劑條件或在適 當溶劑如乙醇、1-曱基-2-吡咯咬酮、N,N-二甲基甲 醯胺、1,4-二畤烷、四氫呋喃、二甲基亞砜、四氫萘、 磺醯烷、乙腈等下於反應-惰性氛圍中進行反應 γΗ (V)α-a-l) 其中,W2為一適當釋離基且γ,Q,Rl,R2, γ' “及 係如申請專利範圍第1項中所定義;,, q 15 C),式(IV)中間體與式(VI)中間體在適當溶劑如认二 巧、二甲基亞碼、四氫萘、績酿燒等中在反應-惰 性氛圍如無氧之氬或氮巾於適當驗如氫化納、氫化 鉀、氫氧化鈉等存在之下進行反應 經濟部智慧財產局員工消費合作社印製(IV)其中,W2為一適當釋離基且γ,Q,Rl,r2, r2' r3及 係如申請專利範圍第丨項中所定義; q 本紙張尺度 -62 1238161 = B〇 C8 _D8_ 六、申請專利範圍 或,如果想要,可根據技藝已知之轉化反應將式(I-a) 化合物互相轉換;且又,如果想要,可藉著用酸處理 將式(I-a)化合物轉化為酸加成鹽,或相反地,可藉著用 驗處理而將酸加成鹽型式轉化為游離驗。 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10779298P | 1998-11-10 | 1998-11-10 | |
US14396299P | 1999-07-15 | 1999-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI238161B true TWI238161B (en) | 2005-08-21 |
Family
ID=26805159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088119614A TWI238161B (en) | 1998-11-10 | 1999-12-23 | HIV replication inhibiting pyrimidines |
Country Status (41)
Country | Link |
---|---|
US (5) | US6878717B2 (zh) |
EP (2) | EP1002795B1 (zh) |
JP (1) | JP3635238B2 (zh) |
KR (1) | KR100658489B1 (zh) |
CN (1) | CN1214013C (zh) |
AP (1) | AP1683A (zh) |
AR (1) | AR024227A1 (zh) |
AT (2) | ATE455107T1 (zh) |
AU (2) | AU762523C (zh) |
BG (1) | BG65103B1 (zh) |
BR (1) | BRPI9915552B8 (zh) |
CA (1) | CA2350801C (zh) |
CY (1) | CY2008021I2 (zh) |
CZ (1) | CZ301367B6 (zh) |
DE (3) | DE69905683T2 (zh) |
DK (1) | DK1002795T3 (zh) |
EA (1) | EA004049B1 (zh) |
EE (1) | EE05086B1 (zh) |
ES (2) | ES2193664T3 (zh) |
FR (1) | FR09C0004I2 (zh) |
HK (2) | HK1025330A1 (zh) |
HR (2) | HRP20010161B9 (zh) |
HU (2) | HU230394B1 (zh) |
ID (1) | ID28376A (zh) |
IL (2) | IL143023A0 (zh) |
LT (1) | LTC1002795I2 (zh) |
LU (1) | LU91528I2 (zh) |
MY (1) | MY121108A (zh) |
NL (1) | NL300373I2 (zh) |
NO (3) | NO318801B1 (zh) |
NZ (1) | NZ511116A (zh) |
OA (1) | OA11674A (zh) |
PL (1) | PL204427B1 (zh) |
PT (1) | PT1002795E (zh) |
SI (1) | SI1002795T1 (zh) |
SK (2) | SK287269B6 (zh) |
TR (1) | TR200101306T2 (zh) |
TW (1) | TWI238161B (zh) |
UA (1) | UA70966C2 (zh) |
WO (1) | WO2000027825A1 (zh) |
ZA (1) | ZA200103769B (zh) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
OA11674A (en) * | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
EA005423B1 (ru) * | 1999-09-24 | 2005-02-24 | Янссен Фармацевтика Н.В. | Противовирусные композиции |
JP2003511378A (ja) | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | トリアジン系キナーゼ阻害薬 |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
ES2542326T3 (es) * | 2000-05-08 | 2015-08-04 | Janssen Pharmaceutica Nv | Inhibidores de la replicación del VIH |
DK1282607T3 (en) * | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
EP1337931A4 (en) * | 2000-11-01 | 2005-05-11 | Snapnames Com Inc | DOMAIN NAME ACQUISITION AND MANAGEMENT SYSTEM AND METHOD |
US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
EP2090571B1 (de) * | 2001-10-17 | 2012-05-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
US7183288B2 (en) | 2001-11-01 | 2007-02-27 | Herwig Josephus Margareta Janssen, legal representative | Amide derivatives as glycogen synthase kinase 3-β inhibitors |
EP1448556A1 (en) | 2001-11-01 | 2004-08-25 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
PL212089B1 (pl) | 2002-03-13 | 2012-08-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja |
KR20040094672A (ko) | 2002-03-13 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체 |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
WO2003093344A1 (en) * | 2002-05-03 | 2003-11-13 | Janssen Pharmaceutica N.V. | Polymeric microemulsions |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
AR040456A1 (es) | 2002-06-27 | 2005-04-06 | Bristol Myers Squibb Co | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
CN101481356B (zh) * | 2002-08-09 | 2012-07-11 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
DK1551372T3 (en) * | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
EA200500721A1 (ru) * | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
MXPA05008368A (es) * | 2003-02-07 | 2005-11-04 | Janssen Pharmaceutica Nv | 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana. |
EP1597237B1 (en) | 2003-02-07 | 2016-07-27 | Janssen Pharmaceutica NV | Pyrimidine derivatives for the prevention of HIV infection |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
WO2005011702A1 (en) * | 2003-07-17 | 2005-02-10 | Tibotec Pharmaceuticals Ltd. | Process for preparing particles containing an antiviral |
CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
WO2005028479A2 (en) * | 2003-09-25 | 2005-03-31 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting purine derivatives |
EP1728186A2 (en) | 2004-03-02 | 2006-12-06 | Virco Bvba | Estimation of clinical cut-offs |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
WO2006010750A1 (en) | 2004-07-28 | 2006-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
RU2401833C2 (ru) | 2004-08-10 | 2010-10-20 | Янссен Фармацевтика Н.В. | Производные 1, 2, 4-триазин-6-она, ингибирующие вич |
TW200626574A (en) * | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-heterocyclyl pyrimidines |
CN101027288B (zh) * | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | 抑制hiv的5-取代嘧啶 |
BRPI0515935B8 (pt) | 2004-09-30 | 2021-05-25 | Janssen Sciences Ireland Uc | pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica |
BRPI0517272A (pt) | 2004-10-29 | 2008-10-07 | Tibotec Pharm Ltd | derivados de pirimidina bicìclicos de inibição de hiv |
CA2583187A1 (en) * | 2004-11-08 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and etravirine |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
AU2006208778B2 (en) | 2005-01-27 | 2012-08-09 | Janssen Sciences Ireland Uc | HIV inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives |
WO2006087530A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
JP5247154B2 (ja) * | 2005-02-18 | 2013-07-24 | テイボテク・フアーマシユーチカルズ | Hiv阻害性2−(4−シアノフェニルアミノ)ピリミジンオキシド誘導体 |
RU2401261C2 (ru) * | 2005-03-04 | 2010-10-10 | Тиботек Фармасьютикалз Лтд. | Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины |
EP1899323A2 (en) | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
MX2007014881A (es) * | 2005-05-26 | 2008-02-15 | Tibotec Pharm Ltd | Procedimiento para preparar 4-(1,6-dihidro-6-oxo-2-pirimidinil) amino benzonitrilo. |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7754773B2 (en) * | 2005-10-06 | 2010-07-13 | University Of Massachusetts | Composition and synthesis of new reagents for inhibition of HIV replication |
BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
EP1979326B1 (en) | 2006-01-19 | 2012-10-03 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
AU2007206950B2 (en) | 2006-01-19 | 2012-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
DK1981874T3 (da) | 2006-01-19 | 2009-09-28 | Janssen Pharmactuica N V | Aminophenylderivater som nye inhibitorer af histondeacetylase |
CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP2004632B1 (en) | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
EP2004641B1 (en) | 2006-03-30 | 2010-09-29 | Tibotec Pharmaceuticals | Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines |
PE20080068A1 (es) | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
WO2007141308A1 (en) * | 2006-06-06 | 2007-12-13 | Tibotec Pharmaceuticals Ltd. | Process for preparing spray dried formulations of tmc125 |
CN101677963B (zh) | 2006-06-19 | 2012-05-30 | 奥尔制药公司 | 药物组合物 |
CA2665726C (en) * | 2006-10-11 | 2016-04-19 | Alpharma, Inc. | Pharmaceutical compositions |
EP2104491B1 (en) | 2006-12-06 | 2017-02-22 | Janssen Sciences Ireland UC | Hydrobromide salt of an anti-hiv compound |
AU2007341228B2 (en) | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
CA2674178C (en) | 2006-12-29 | 2015-11-10 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 6-substituted pyrimidines |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
EP2212298B1 (en) * | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US20090196890A1 (en) * | 2007-12-17 | 2009-08-06 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
CA2723961C (en) | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
BRPI0914682B8 (pt) | 2008-06-27 | 2021-05-25 | Avila Therapeutics Inc | compostos de heteroarila e composições compreendendo os referidos compostos |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
TW201016676A (en) * | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
CN102369009B (zh) | 2009-03-30 | 2014-04-30 | 泰博特克药品公司 | 依曲韦林和烟酰胺的共晶体 |
CN102482277B (zh) | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
WO2010131118A2 (en) * | 2009-05-12 | 2010-11-18 | Pliva Hrvatska D.O.O. | Polymorphs of etravirine and processes for preparation thereof |
EP2342186B1 (en) | 2009-06-22 | 2014-09-17 | Emcure Pharmaceuticals Limited | Process for synthesis of etravirine |
US8153790B2 (en) | 2009-07-27 | 2012-04-10 | Krizmanic Irena | Process for the preparation and purification of etravirine and intermediates thereof |
GR1007010B (el) | 2009-10-08 | 2010-10-07 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Ινσουλινοειδη πεπτιδια |
CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
WO2012001695A1 (en) | 2010-06-28 | 2012-01-05 | Hetero Research Foundation | A process for etra virine intermediate and polymorphs of etravirine |
KR20130099040A (ko) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Btk 억제제의 베실레이트 염 |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
BR112013010564B1 (pt) | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
ES2665013T3 (es) | 2010-11-10 | 2018-04-24 | Celgene Car Llc | Inhibidores de EGFR selectivos de mutante y usos de los mismos |
HUE046617T2 (hu) | 2010-11-10 | 2020-03-30 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
PL2702045T3 (pl) | 2011-04-26 | 2018-04-30 | Mylan Laboratories Ltd. | Nowy sposób sporządzania Etrawiryny |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
WO2012170647A1 (en) * | 2011-06-09 | 2012-12-13 | Assia Chemical Industriew Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
ES2690971T3 (es) | 2011-08-23 | 2018-11-23 | Asana Biosciences, Llc | Compuestos pirimido-piridazinona y uso de los mismos |
WO2013059572A1 (en) | 2011-10-19 | 2013-04-25 | Assia Chemical Industries Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
WO2013109354A2 (en) * | 2011-12-07 | 2013-07-25 | Texas Southern University | Etravirine formulations and uses thereof |
EP2825042B1 (en) | 2012-03-15 | 2018-08-01 | Celgene CAR LLC | Salts of an epidermal growth factor receptor kinase inhibitor |
BR112014022789B1 (pt) | 2012-03-15 | 2022-04-19 | Celgene Car Llc | Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
US20150336900A1 (en) * | 2012-10-29 | 2015-11-26 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the Synthesis of Etravirine and Its Intermediates |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
MX2015007945A (es) | 2012-12-21 | 2016-02-16 | Verlyx Pharma Inc | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
CN104926829A (zh) * | 2015-06-08 | 2015-09-23 | 山东大学 | 一种噻吩并嘧啶类衍生物及其制备方法和应用 |
ES2929526T3 (es) | 2015-06-22 | 2022-11-29 | Arena Pharm Inc | Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1 |
CN110066273A (zh) * | 2019-06-05 | 2019-07-30 | 山东大学 | 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 |
WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
CN111217833B (zh) * | 2020-02-21 | 2021-03-16 | 山东大学 | 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用 |
CN111875548A (zh) * | 2020-07-16 | 2020-11-03 | 山东大学 | 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US4659363A (en) * | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
US4694009A (en) * | 1984-06-25 | 1987-09-15 | Ciba-Geigy Corporation | Pesticidal compositions |
DE68918804T2 (de) | 1988-03-31 | 1995-02-23 | Mitsubishi Chem Ind | Acyclische 6-substituierte pyrimidin nukleosid-abkömmlinge und antivirale mittel, die dieselben als aktive mittel enthalten. |
JPH02308248A (ja) | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
JP2895680B2 (ja) * | 1992-07-08 | 1999-05-24 | シャープ株式会社 | 磁気ヘッドおよびその製造方法 |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
RU2153494C2 (ru) * | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
HUP9900730A3 (en) | 1995-11-23 | 2001-04-28 | Janssen Pharmaceutica Nv | Solid mixtures of cyclodextrins prepared via melt-extrusion |
KR100219922B1 (ko) * | 1996-05-16 | 1999-09-01 | 이서봉 | 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법 |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
DE29704863U1 (de) * | 1997-03-17 | 1997-05-22 | Ges Innenhochdruckverfahren | Achsschwinge |
CA2321153A1 (en) | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
EP0945442A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted pyrimidine derivatives |
WO1999050250A1 (en) * | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
DE69943247D1 (de) * | 1998-03-27 | 2011-04-14 | Janssen Pharmaceutica Nv | HIV hemmende Pyrimidin Derivate |
OA11674A (en) * | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
DK1282607T3 (en) * | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
-
1999
- 1999-09-24 OA OA1200100113A patent/OA11674A/en unknown
- 1999-09-24 SK SK603-2001A patent/SK287269B6/sk active Protection Beyond IP Right Term
- 1999-09-24 CA CA002350801A patent/CA2350801C/en not_active Expired - Lifetime
- 1999-09-24 AP APAP/P/2001/002121A patent/AP1683A/en active
- 1999-09-24 EE EEP200100252A patent/EE05086B1/xx active Protection Beyond IP Right Term
- 1999-09-24 EA EA200100536A patent/EA004049B1/ru active IP Right Revival
- 1999-09-24 IL IL14302399A patent/IL143023A0/xx active Protection Beyond IP Right Term
- 1999-09-24 AU AU62008/99A patent/AU762523C/en not_active Revoked
- 1999-09-24 SK SK5012-2009A patent/SK287270B6/sk not_active IP Right Cessation
- 1999-09-24 TR TR2001/01306T patent/TR200101306T2/xx unknown
- 1999-09-24 HU HU1100091A patent/HU230394B1/hu unknown
- 1999-09-24 BR BRPI9915552A patent/BRPI9915552B8/pt not_active IP Right Cessation
- 1999-09-24 CN CNB998119180A patent/CN1214013C/zh not_active Expired - Lifetime
- 1999-09-24 UA UA2001042857A patent/UA70966C2/uk unknown
- 1999-09-24 KR KR1020017003576A patent/KR100658489B1/ko active IP Right Grant
- 1999-09-24 HU HU0104177A patent/HU227453B1/hu active Protection Beyond IP Right Term
- 1999-09-24 ID IDW00200101015A patent/ID28376A/id unknown
- 1999-09-24 JP JP2000581005A patent/JP3635238B2/ja not_active Expired - Lifetime
- 1999-09-24 WO PCT/EP1999/007417 patent/WO2000027825A1/en active Application Filing
- 1999-09-24 NZ NZ511116A patent/NZ511116A/en not_active IP Right Cessation
- 1999-09-24 PL PL347586A patent/PL204427B1/pl unknown
- 1999-09-24 CZ CZ20011533A patent/CZ301367B6/cs not_active IP Right Cessation
- 1999-11-01 AT AT02018455T patent/ATE455107T1/de not_active IP Right Cessation
- 1999-11-01 AT AT99203590T patent/ATE233740T1/de active
- 1999-11-01 EP EP99203590A patent/EP1002795B1/en not_active Expired - Lifetime
- 1999-11-01 ES ES99203590T patent/ES2193664T3/es not_active Expired - Lifetime
- 1999-11-01 DE DE69905683T patent/DE69905683T2/de not_active Expired - Lifetime
- 1999-11-01 ES ES02018455T patent/ES2338760T3/es not_active Expired - Lifetime
- 1999-11-01 SI SI9930275T patent/SI1002795T1/xx unknown
- 1999-11-01 EP EP02018455A patent/EP1270560B1/en not_active Expired - Lifetime
- 1999-11-01 PT PT99203590T patent/PT1002795E/pt unknown
- 1999-11-01 DE DE122009000003C patent/DE122009000003I1/de active Pending
- 1999-11-01 DE DE69941934T patent/DE69941934D1/de not_active Expired - Lifetime
- 1999-11-01 US US09/430,966 patent/US6878717B2/en not_active Expired - Lifetime
- 1999-11-01 DK DK99203590T patent/DK1002795T3/da active
- 1999-11-05 MY MYPI99004805A patent/MY121108A/en unknown
- 1999-11-09 AR ARP990105680A patent/AR024227A1/es active IP Right Grant
- 1999-12-23 TW TW088119614A patent/TWI238161B/zh not_active IP Right Cessation
-
2000
- 2000-07-26 HK HK00104633A patent/HK1025330A1/xx not_active IP Right Cessation
-
2001
- 2001-03-07 HR HRP20010161AA patent/HRP20010161B9/hr not_active IP Right Cessation
- 2001-04-04 NO NO20011696A patent/NO318801B1/no not_active IP Right Cessation
- 2001-04-06 BG BG105418A patent/BG65103B1/bg unknown
- 2001-05-09 ZA ZA200103769A patent/ZA200103769B/en unknown
-
2003
- 2003-02-14 HK HK03101063.7A patent/HK1048817B/zh not_active IP Right Cessation
- 2003-08-05 US US10/634,682 patent/US7037917B2/en not_active Expired - Lifetime
-
2005
- 2005-07-28 IL IL169949A patent/IL169949A/en not_active IP Right Cessation
- 2005-08-16 US US11/204,513 patent/US20050288278A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/930,835 patent/US8003789B2/en not_active Expired - Fee Related
-
2008
- 2008-07-17 HR HRP20080359AA patent/HRP20080359B1/hr not_active IP Right Cessation
- 2008-12-03 LT LTPA2008016C patent/LTC1002795I2/lt unknown
- 2008-12-10 CY CY2008021C patent/CY2008021I2/el unknown
-
2009
- 2009-01-13 NL NL300373C patent/NL300373I2/nl unknown
- 2009-01-22 FR FR09C0004C patent/FR09C0004I2/fr active Active
- 2009-02-18 LU LU91528C patent/LU91528I2/fr unknown
- 2009-02-23 NO NO2009003C patent/NO2009003I2/no unknown
-
2011
- 2011-02-18 AU AU2011200708A patent/AU2011200708A1/en active Pending
- 2011-07-06 US US13/177,188 patent/US8530655B2/en not_active Expired - Fee Related
-
2021
- 2021-03-29 NO NO2021015C patent/NO2021015I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI238161B (en) | HIV replication inhibiting pyrimidines | |
TW531534B (en) | HIV inhibiting pyrimidine derivatives | |
CN101094853B (zh) | 可用作蛋白激酶抑制剂的吡唑并[1,5-a]嘧啶 | |
CN101001857B (zh) | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 | |
EA005423B1 (ru) | Противовирусные композиции | |
TW200406374A (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
CN101952274A (zh) | 非核苷逆转录酶抑制剂 | |
CN101932583A (zh) | 用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类 | |
TW202045159A (zh) | 藥物配製物 | |
CN107438598A (zh) | 喹唑啉和喹啉化合物及其用途 | |
CN101316587B (zh) | 取代的吡唑化合物 | |
TW541305B (en) | 2,4-disubstituted triazine derivatives | |
MXPA01003646A (en) | Hiv replication inhibiting pyrimidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |